Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- ---
EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000.
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT
___ OF 1934. FOR THE TRANSITION PERIOD _______ TO _______.
Commission File Number: 0-20727
Novoste Corporation
(Exact Name of Registrant as Specified in Its Charter)
Florida 59-2787476
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
3890 Steve Reynolds Blvd., Norcross, GA 30093
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone, including area code: (770) 717-0904
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 par value
(Title of Class)
Rights to Purchase Preferred Shares
(Title of Class)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
requirements for the past 90 days. Yes ___ No ___
Indicate by check mark if disclosures of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K ( ).
As of February 28, 2001, there were 16,100,165 shares of Common Stock
outstanding. The aggregate market value of voting stock held by non-affiliates
of the Registrant was approximately $539,355,528 based upon the closing sales
price of the Common Stock on February 28, 2001 on the Nasdaq National Market.
Shares of Common Stock held by each officer, director, and holder of five
percent or more of the Common Stock outstanding as of February 28, 2001 have
been excluded in that such persons may be deemed to be affiliates. This
determination of affiliate status is not necessarily conclusive.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of Registrant's Proxy Statement for its 2000 Annual Meeting of
Stockholders, which the Registrant intends to file not later than 120 days
following December 31, 2000, are incorporated by reference to Part III of this
Form 10-K Report.
1
NOVOSTE CORPORATION
FORM 10-K
INDEX
PART I.
Item 1. Business.................................................... 3
Item 2. Properties.................................................. 20
Item 3. Legal Proceedings........................................... 20
Item 4. Submission of Matters to a Vote of Security Holders......... 20
Item 4a. Executive Officers of the Registrant........................ 20
PART II.
Item 5. Market for Registrant's Common Equity and Related
Stockholder Matters......................................... 21
Item 6. Selected Consolidated Financial Data........................ 21
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations......................... 22
Item 7a. Quantitative and Qualitative Disclosures About
Market Risk................................................. 26
Item 8. Consolidated Financial Statements and Supplementary
Data........................................................ 27
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure......................... 27
PART III.
Item 10. Directors and Executive Officers of The Registrant.......... 28
Item 11. Executive Compensation...................................... 28
Item 12. Security Ownership of Certain Beneficial Owners
and Management.............................................. 28
Item 13. Certain Relationships and Related Transactions.............. 28
PART IV.
Item 14. Exhibits, Consolidated Financial Statement
Schedules, and Reports on Form 8-K.......................... 29
2
PART I
Item 1. BUSINESS
In this Form 10-K, "Novoste," the "Company," "we," "us" and "our" refer to
Novoste Corporation. Novoste(R), Beta-Cath(TM) and the Novoste(R) logo are
trademarks of the Company.
GENERAL
Novoste has developed the Beta-Cath(TM) System, a hand-held device to
deliver beta, or low penetration, radiation to the site of a treated blockage in
a coronary artery to decrease the likelihood of restenosis. Restenosis, the
renarrowing of a previously treated artery, is the major limitation of
percutaneous coronary intervention or PTCA, a procedure used by interventional
cardiologists to open blocked coronary arteries. In August 1998, we qualified to
apply CE marking to the Beta-Cath(TM) System, a requirement to sell our device
in most of Western Europe and commenced the active marketing of our device in
Western Europe in January, 1999. On November 3, 2000, Novoste received U.S.
marketing approval from the FDA for the Beta-Cath(TM) System (30-millimeter
source train) for use in patients suffering from "in-stent restenosis", a
condition in which previously placed coronary stents become clogged with new
tissue growth. We are also seeking approval from the FDA to market the Beta-
Cath(TM) System using a 40-millimeter source train and anticipate receiving
approval in the second quarter of 2001.
In 2000 physicians performed approximately 800,000 PTCA procedures in the
United States and approximately 600,000 PTCA procedures abroad. Studies have
shown that 30% to 50% of patients experience restenosis within six months after
PTCA. Restenosis often requires one or more additional revascularization
procedures to reopen blocked vessels. These procedures include PTCA, which has
an average cost of $20,000 in the United States, and coronary artery bypass
graft surgery, or CABG, which has an average cost of $45,000 in the United
States. It is estimated that more than $3.0 billion is spent annually in the
United States on revascularization procedures.
In response to the high rates of restenosis following PTCA, the placement of
coronary stents, metal implants that prop open a coronary artery, has grown
rapidly. In 2000, stents were used in approximately 75% of all PTCA procedures
performed worldwide and on average added over $2,000 to the cost of each PTCA
procedure. However, studies have shown that restenosis still occurs in
approximately one-third of the patients who receive stents. This is commonly
referred to as "in-stent" restenosis. Patients with "in-stent" restenosis often
experience recurrent restenosis and as a result are prone to multiple
revascularization procedures. Data from our START Trial demonstrate that the
Beta-Cath(TM) System is safe and effective in treating patients with in-stent
restenosis and this supported our marketing approval from the FDA in late 2000.
INDUSTRY OVERVIEW
Coronary Artery Disease. Coronary artery disease is the leading cause of
death in the United States. More than 13 million people in the United States
currently suffer from coronary artery disease, which is generally characterized
by the progressive accumulation of plaque as a result of the deposit of
cholesterol and other fatty materials on the walls of the arteries. The
accumulation of plaque leads to a narrowing of the interior passage, or lumen,
of the arteries, thereby reducing blood flow to the heart muscle. When blood
flow to the heart muscle becomes insufficient, oxygen supply is restricted and a
heart attack and death may result. Depending on the severity of the disease and
other variables, patients will be treated either surgically with CABG or less
invasively with a PTCA procedure.
Coronary Artery Bypass Graft Surgery. Coronary artery bypass graft surgery,
or CABG, was introduced as a treatment for coronary artery disease in the
1950's. CABG is a highly invasive, open surgical procedure in which blood vessel
grafts are used to bypass the site of a blocked artery, thereby restoring blood
flow. CABG, still considered the most durable treatment for coronary artery
disease, is generally the primary treatment for severe coronary artery disease
involving multiple vessels. In addition, CABG is often a treatment of last
resort for patients who have undergone other less invasive procedures like PTCA
but require revascularization. However, CABG has significant limitations,
including medical complications such as stroke, multiple organ dysfunction,
inflammatory response, respiratory failure and post-operative bleeding, each of
which may result in death. In addition, CABG is a very expensive procedure and
requires a long recovery period. In the United States, the average cost of
undergoing CABG, including hospital stay, is approximately $45,000; and the
average recuperation period following discharge from the hospital is at least
four to six weeks. In 2000, approximately 400,000 CABG procedures were performed
in the United States. Several new minimally invasive surgical techniques have
been commercialized which attempt to lessen the cost and trauma of CABG
procedures while maintaining efficacy.
3
PTCA. Since its introduction in the late 1970s, PTCA has emerged as the
principal less invasive alternative to CABG. PTCA is a procedure performed in a
cath lab by an interventional cardiologist. During PTCA, a guidewire is inserted
into a blood vessel through a puncture in the leg (or arm, in some cases) and
guided through the vasculature to a diseased site in the coronary artery. A
balloon-tipped catheter is then guided over the wire to the deposit of plaque or
lesion occluding the artery. Once the balloon is positioned across the lesion
inside the vessel, the balloon is inflated and deflated several times.
Frequently, successively larger balloons are inflated at the lesion site,
requiring the use of multiple balloon catheters. The inflation of the balloon
cracks or reshapes the plaque and the arterial wall, thereby expanding the
arterial lumen and increasing blood flow. However, the inflation of the balloon
typically results in injury to the arterial wall. In 2000, it is estimated that
about 800,000 PTCA procedures were performed in the United States and
approximately 600,000 procedures were performed outside the United States. The
average cost of each PTCA procedure in the United States is approximately
$20,000, or less than one-half of the average cost of CABG. The length of stay
and recuperation period are substantially less than those required for CABG.
Though PTCA has grown rapidly as a highly effective, less invasive therapy
to treat coronary artery disease, the principal limitation of PTCA is the high
rate of restenosis, the renarrowing of a treated artery, which often requires
reintervention. Studies have indicated that, within six months after PTCA,
between 30% and 50% of PTCA patients experience restenosis.
Pathology of Restenosis. Restenosis is typically defined as the renarrowing
of a treated coronary artery within six months of a revascularization procedure
such as PTCA to less than 50% of its normal size. Restenosis is a vascular
response to the arterial trauma caused by PTCA. Due to multiple mechanisms
controlling vascular repair, restenosis may occur within a short period after a
revascularization procedure or may develop over the course of months or years.
Restenosis that occurs within a day of a revascularization procedure is
usually attributed to elastic recoil (acute loss of diameter) of the artery.
Restenosis also may result from hyperplasia, which is the excessive
proliferation of cells at the treatment site, or from vascular remodeling of the
arterial segment, which is a slow contraction of a vessel wall. Hyperplasia is a
physiological response to injury, similar to scarring, which occurs in wound
healing. Vascular remodeling is a contraction of the vessel caused by a
thickening of the outside wall of the artery. In response to an arterial injury
from revascularization, the body sets off a biochemical response to repair the
injured site and protect it from further harm. This response will include a
signal to adjacent cells of the arterial wall to multiply. Often this cell
proliferation goes unchecked, resulting in a much thicker and inelastic arterial
wall and in reduced blood flow. Hyperplasia and vascular remodeling are the
primary causes of restenosis.
Coronary Stenting. Coronary stents are expandable, implantable metal devices
permanently deployed at a lesion site. Stents maintain increased lumen diameter
by mechanically supporting the diseased site in a coronary artery. Of all the
non-surgical treatments seeking to improve upon PTCA, stents have been the most
successful in improving the outcome immediately following the procedure and
reducing the incidence of restenosis. In a typical stent procedure, the artery
is pre-dilated at the lesion site with a balloon catheter, and the stent is
delivered to the site of the lesion and deployed with the use of a second
balloon catheter which expands the stent and firmly positions it in place. This
positioning may be followed by a third expansion, using a high-pressure balloon
to fully deploy and secure the stent. Once placed, stents exert radial force
against the walls of the coronary artery to enable the artery to remain open and
functional.
Studies have concluded that the rate of restenosis in patients receiving
coronary stents following PTCA is approximately 30% lower than in patients
treated only by PTCA. Since their commercial introduction in the United States
in 1994, the use of stents has grown rapidly, and it is estimated that they were
utilized in approximately 75% of the approximately 1.4 million PTCA procedures
performed in 2000.
Despite their rapid adoption, stents have certain drawbacks. The use of
stents increases the cost of a PTCA procedure, especially when, as is often the
case, two or more stents are used. In addition, studies have shown that
restenosis still occurs in approximately 30% to 40% of the patients who receive
stents following PTCA. This is commonly referred to as "in-stent" restenosis.
Studies have shown that patients with "in-stent" restenosis often experience
recurrent restenosis and as a result are prone to multiple revascularization
procedures. Stents are also permanent implants which may result in unforeseen,
long-term adverse effects, and cannot be used in cases where the coronary
arteries are too tortuous or too narrow. Further, stents appear to be effective
in reducing the frequency of restenosis resulting from elastic recoil and
vascular remodeling, but they increase the degree of hyperplasia.
THE NOVOSTE SOLUTION
The Beta-Cath(TM) System has been shown to reduce the incidence of
restenosis in patients who are being treated for blocked stents, or in-stent
restenosis. The administration of localized beta radiation reduces
4
restenosis rates by inhibiting hyperplasia and vascular remodeling. Radiation
has been used therapeutically in medicine for more than 50 years in the
treatment of proliferative cell disorders, such as cancer. Cancer therapy has
primarily involved the use of gamma radiation, which is highly penetrating and
may be hazardous unless handled and used with great care. By contrast, beta
radiation is far less penetrating and easier to use and shield than gamma
radiation while still delivering a sufficient dose to the treated coronary
arteries. We view beta radiation as well-suited for intracoronary use following
PTCA, where the objective is to treat the coronary artery with minimal exposure
to adjacent tissues.
The Beta-Cath(TM) System is designed to fit well with techniques currently
used by interventional cardiologists in the cath lab. It is a hand-held device
that hydraulically delivers beta radiation sources through a closed-end catheter
to the area of the coronary artery injured by the immediately preceding PTCA
procedure. To facilitate easy placement of the catheter, it is advanced over the
same guidewire used in the PTCA procedure. After the administration of the
prescribed radiation dose to a lesion site, which takes less than five minutes
per lesion, the radiation sources are hydraulically returned to the hand-held
transfer device. We expect to be able to reuse the radiation isotopes for up to
a eighteen months due to the long half-life of Strontium-90, the isotope used in
Novoste device.
OUR BUSINESS STRATEGY
Our objective is to build and maintain our leadership position in the
vascular brachytherapy market. Elements of our strategy include:
- Achieving First-to-Market Position and a Leading Market Share in the
United States and Europe. We were the first-to-market in the United
States with a vascular brachytherapy device in November 2000, shortly
after receiving FDA approval of the Beta Cath(TM) System for treatment
of patients with in-stent restenosis. Likewise we were the first company
with approval to market a vascular brachytherapy device in Europe,
having received CE marketing certification in August 1998. We believe
that being first-to-market may provide a competitive advantage since
most hospitals are unlikely to purchase more than one or two vascular
brachytheraphy devices due to the complex inventory management and
logistics, radiation licensing hurdles, and diverse training
requirements associated with various competing systems.
- Establishing the Beta-Cath(TM) System as the Standard of Care for
In-Stent Restenosis Treatment. Our strategy is to introduce the Beta-
Cath(TM) System into the cath lab as the standard of care for treating
patients with blocked stents. In addition, we intend to conduct
intensive physician-training seminars to familiarize interventional
cardiologists and radiation oncologists with the use of the Beta-
Cath(TM) System.
- Selling Directly. We market the Beta-Cath(TM) System in the United
States through a direct sales force. Our initial marketing efforts are
focused on the top tier of approximately 250 high-volume hospitals and
on leading interventional cardiologists and radiation oncologists at
those institutions. The interventional cardiologists at these hospitals
perform a large portion of the PTCA procedures in the United States and
tend to adopt new cardiovascular technologies and devices quickly. We
also believe we can leverage the reputation of these early adopters in
the clinical community to generate wider demand. In addition, we believe
these hospitals have or will be able to obtain relatively quickly the
necessary licenses to store and use our beta radiation source and are
likely to have radiation oncologists with the appropriate credentials to
use the Beta-Cath(TM) System's radiation sources. We also market the
Beta-Cath(TM) System in Europe through a direct sales force in larger
markets, which we have supplemented with independent distributors in
other markets.
- Continuous Product Improvements and Line Extensions. We plan to make
continuous product improvements to the Beta-Cath(TM) System in response
to customer interests and future competitive products. For example,
Novoste has designed a smaller diameter catheter system to enable
cardiologists to treat patients with smaller arteries, which are more
susceptible to restenosis. In addition, we intend to expand our current
product offering in the United States with the addition of products that
are already available in Europe, such as the 40-mm and 60-mm radiation
source train versions of the Beth-Cath(TM) System.
- Investigating the Beth-Cath(TM) System for Other Vascular Applications.
We believe that the most attractive markets for vascular brachytherapy
are those clinical indications in which patients are not well served by
conventional therapies such as balloon angioplasty or coronary stents.
In addition to in-stent restenosis, these applications include "high
risk PTCA", or patients who are at high risk of restenosis after PTCA
(those with small vessels or long diffuse disease), and patients with
saphenous vein grafts that have become blocked. Restenosis is also
common after revascularization of peripheral or non-coronary arteries.
In addition, a similar phenomenon frequently occurs in veins adjacent to
an arterial-venous shunt used for patients undergoing hemodialysis for
end-stage renal disease. We intend to leverage our core catheter and
localized vascular brachytherapy technologies to expand our product
offerings to other vascular markets where cell proliferation is of
clinical significance and radiation results in improved clinical
efficacy.
- Protecting and Enhancing our Proprietary Technology. We believe that our
patent position may offer a competitive advantage. On November 4, 1997
we were issued United States Patent No. 5,683,345 on the Beta-Cath
System, on May 4, 1999 we received United States Patent No. 5,899,882
and on January 11, 2000 we received United States Patent No. 6,013,020.
We have also filed a related United States continuation-in-part
application (which is jointly owned by us and Emory University), and
have additional United States applications pending covering aspects of
our Beta-Cath(TM) System. With respect to
5
our United States filings, we have filed, or will file in due course,
counterpart applications in the European Patent Office and certain other
countries. We intend to obtain further protection of our proprietary
technology and to defend our intellectual property rights against
infringement.
BETA-CATH(TM) SYSTEM DESIGN AND ADVANTAGES
The primary components of the Beta-Cath(TM) System are:
Radiation Source Train. The beta radiation administered by the Beta-Cath(TM)
System emanates from a "train" of several miniature sealed sources containing
Strontium 90 (Strontium/Yttrium), a beta-emitting radioisotope. We currently
manufacture trains in both 30mm, 40mm and 60mm lengths, with the longer length
intended for use on longer lesions. The use of beta, rather than gamma,
radiation is intended to make the Beta-Cath(TM) System safer and easier to use
in the cath lab environment. In addition, due to the long half-life
(approximately 28 years) of Strontium 90, and because the source train will not
come into contact with a patient's blood or tissue, the radiation sources are
expected to be reused for up to eighteen months. Beta radiation from the
Strontium 90 source is easily shielded from health care workers by the use of
approximately one-half-inch-thick quartz in the transfer device.
Transfer Device. The transfer device is a multiple-use, hand-held instrument
used to deliver, retrieve and then store the radiation sources when not in use.
The transfer device:
- transfers the radiation sources to and from the delivery catheter via a
proprietary hydraulic delivery system;
- contains a radiation source sensing system which is interlocked with a
gating system to prevent the radiation sources from exiting the transfer
device until the delivery catheter is locked in place and to prevent
removal of the delivery catheter prior to the return of the radiation
sources to the transfer device; and
- completely shields the beta radiation from health care workers when the
radiation source train is housed inside it.
Delivery Catheter. The delivery catheter is a single-use, multi-lumen
catheter that provides a pathway for the radiation sources to be rapidly
delivered and retrieved from the coronary arterial segment to be treated. The
delivery catheter is positioned by advancing it over the same guidewire used
during the immediately preceding PTCA procedure. The radiation sources are
delivered and retrieved through a dual-lumen closed hydraulic circuit, which
uses a fluid-filled standard syringe to create the hydraulic pressure. We
currently intend to sell a version of the catheter in the United States that
fits over most of the length of the guidewire used in the PTCA procedure,
commonly known as an "over the wire" catheter, and to have our European
subsidiaries sell a version that fits over the guidewire for only a small
portion of the catheter at its far end, commonly known as a "rapid exchange"
catheter.
The Beta-Cath(TM) System is used in a cath lab by an interventional
cardiologist in conjunction with a radiation oncologist. The cardiologist places
the delivery catheter into the patient's vasculature until the catheter reaches
the targeted site. The radiation oncologist operates the transfer device to
deliver the radiation source train hydraulically to the end of the catheter in a
matter of seconds. The radiation sources remain at the targeted site for less
than five minutes to deliver a predetermined dose of radiation. The radiation
sources are then returned by the use of positive hydraulic pressure applied
through a different lumen of the delivery catheter. Upon completion of each
procedure, the train of radiation sources is stored safely inside the transfer
device. At the end of the day, the transfer device is delivered to a designated
radiation storage site within the hospital for safekeeping. While the need for a
cardiologist and a radiation oncologist is expected to result in incremental
physician fees, we believe the Beta-Cath(TM) System will be cost-effective,
principally by reducing the need for costly revascularization procedures often
required following treatment of in-stent restenosis.
We believe the Beta-Cath(TM) System has the following advantages:
- Site-specific Therapy. The Beta-Cath(TM) System is designed to confine
radiation exposure to the targeted intervention area.
- Short Procedure Times. The Beta-Cath(TM) System is designed to enhance
patient safety and comfort, as well as to promote productivity in the
cath lab, by delivering the recommended dosage in less than five minutes
of radiation exposure per lesion.
- Utilization of Existing PTCA Techniques. Although intracoronary
radiation is a new concept in coronary artery disease treatment, the
hand-held Beta-Cath(TM) System is designed to be easily adopted and used
by the interventional cardiologist. The Beta-Cath(TM) System is very
similar to other catheter-based tools used by the cardiologist.
6
- Multiple-Use System. The radiation source train can be reused for
numerous patients, due to the long half-life of the isotope and because
the source train does not come into contact with the patient's blood. As
a result, inventory planning is very straightforward, and last minute
treatment decisions can be made.
- Ease of Use and Accuracy of Dosing. The Beta-Cath(TM) System is a hand-
held device that is easy to operate. Because of the long half-life of
our radiation source, prescribed treatment times will remain constant
over the approved shelf life of the isotope. Vascular brachytherapy
systems that utilize short half-life isotopes are likely to require
complex case-by-case dose calculations based on the current decay state
of the isotope. In addition, they require frequent inventory replacement
due to their short half-lives.
- Designed for Safety. The Beta-Cath(TM) System utilizes localized beta
radiation, which results in total body radiation exposure significantly
less than that received during routine x-ray during PTCA or during
treatment with a gamma radiation device. Other safety mechanisms
include: a closed-source train lumen, special locking mechanisms to
connect the delivery catheter to the transfer device and sufficient
shielding in the transfer device to protect health care workers from
beta radiation exposure. In addition, the beta radiation sources are
delivered and, following the administration of the prescribed dose,
retrieved hydraulically in a matter of seconds, thereby minimizing
exposure to adjacent tissue.
CLINICAL TRIALS
START 30 Trial. On September 21, 1998, we initiated the "Stents And
--------------
Radiation Therapy Trial" or START Trial, a randomized, triple-masked, placebo-
controlled, multicenter human clinical trial, under an investigational device
exemption granted by the FDA, The primary endpoint of this trial was target
vessel revascularization ("TVR"), the incidence of an additional
revascularization procedure in the vessel originally treated within eight
months. The START 30 Trial sought to determine the safety and effectiveness of
the 30mm version of the Beta-Cath(TM) System (30mm System) in treating "in-
stent" restenosis. We divided patients into two approximately equal subgroups,
one receiving vascular brachytherapy through the Beta-Cath(TM) System and the
other receiving no vascular brachytherapy through a placebo version of the
Beta-Cath(TM) System. Patients who received the beta radiation received dosages
of 18 gray for vessels ranging from 2.70 to 3.35mm and 23 gray for vessels
ranging from 3.36 to 4.00mm, slightly higher doses than those used in our Beta-
Cath(TM) System Trial because of radiation shielding from stents previously
implanted in a procedure unrelated to this trial. Although the START 30 Trial
protocol discouraged the placement of new stents, approximately 23% of the
enrolled patients received new stents. We surpassed our targeted enrollment of
386 patients, and enrollment in this trial was completed as of April 30, 1999. A
total of 476 patients were enrolled at 51 sites, located principally in the
United States. Follow-up angiograms eight months after the initial treatment
were performed to observe the treated artery. The angiograms were then analyzed
to determine if there had been any incidence of restenosis and to measure late
loss index. In March 2000, we announced the results of the START Trail showing
statistically significant results for patients with "in stent" restenosis
treated with the 30mm System when compared to patients treated with placebo. In
those patients treated with the 30mm system, the rate of restenosis decreased by
66% at the stented portion of the treated artery and by 36% at a longer section
of the artery, beyond that treated with radiation or revascularization methods.
The START Trial was the basis for the FDA approval of the 30mm system in
November, 2000.
Summary Results of the START 30 Trial
- --------------------------------------------------------------------------------
Beta Placebo
Radiation Control Percent
Angiographic Results (N=244) (N=232) Reduction
- --------------------------------------------------------------------------------
Restenosis Rate/1/:
Stent Segment 14% 41% 66%
Total Analysis Segment 29% 45% 36%
Clinical Outcomes:
Target Lesion Revascularization (TLR)/2/ 13% 22% 42%
Target Vessel Revascularization (TVR)/3/ 16% 24% 34%
Major Adverse Cardiac Events (MACE)/4/ 18% 26% 31%
- --------------------------------------------------------------------------------
START 40 Trial. In addition, on June 22, 1999 we initiated the START
--------------
40 Trial. This multicenter clinical trial enrolled 207 patients who received
vascular brachytherapy using a 40mm active radiation source train. The START 40
Trial had an identical protocol design to the START Trial and, therefore, we
used the START Trial's control group in analyzing the clinical data from the
START 40 Trial. The purpose of this trial is to gain regulatory approval for the
longer 40mm radiation source train. Enrollment in this trial of 207 patients was
completed on October 22, 1999. We believe the 40mm radiation source train is
helpful in addressing clinical concerns over the possibility of "geographic
miss" during a vascular brachytherapy procedure. Geographic miss is the failure
to delivery radiation to the intended target balloon-injury area either due to
poor alignment of the radiation source train with the balloon-induced injury, or
using too short a radiation source train compared to the balloon injury.
7
In November, 2000, results from the analysis of the eight month follow-up
angiograms were released. The data, as also seen in START 30, demonstrated
significant reduction in restenosis in patients treated with beta radiation. In
those patients treated with the 40-millimeter source train with the Beta-
Cath(TM) System, compared to those treated with a placebo, a 63% decrease in the
rate of restenosis was observed in the stented portion of the treated artery and
a 44% decrease was observed in the longer section of the artery, beyond the area
treated with radiation or revascularization methods.
In late December, 2000 a submission was made to the FDA seeking approval to
market the Beta-Cath(TM) System using the 40-millimeter source train. This
submission is currently undergoing review and we anticipate receiving FDA
approval in the second quarter of 2001.
Beta-Cath(TM) System Trial
Trial Design. Designed in 1996 and begun in July 1997, the Beta-Cath(TM)
------------
System Trial was the first randomized, multicenter, placebo-controlled study of
vascular brachytherapy. Vascular brachytherapy is radiation therapy delivered
inside an artery with the objective of reducing the incidence of restenosis. The
Trial was also the first pivotal study to evaluate intracoronary radiation in
the primary prevention of coronary restenosis subsequent to either PTCA
("percutaneous transluminal coronary angioplasty" or "balloon angioplasty") or
first time stent placement.
The Beta-Cath(TM) System Trial was originally designed to enroll 1,100
patients into one of two branches, either the PTCA branch or the Provisional
Stent branch. According to the clinical trial protocol, patients enrolled in the
Trial were initially treated with balloon angioplasty. If the cardiologist
achieved a satisfactory result, the patient would remain in the PTCA branch and
then be treated with the Beta-Cath(TM) System. If balloon angioplasty was sub-
optimal, the patient would be entered into the Provisional Stent branch. Prior
to stent placement, the patient would be treated with the Beta-Cath(TM) System,
after which a stent would be implanted. All patients were randomized to either
an inactive (placebo) or active 30-mm Strontium-90 (beta radiation) source
train, and treatment times ranged from two to four minutes. On average, patients
enrolled in the study had 12.5-mm long lesions in arteries 3.0-mm in diameter.
Depending on the artery diameter, a dose of either 16 or 21 gray was
administered. Patients returned for follow-up examinations eight months after
the vascular brachytherapy procedure.
In March 1999, the Trial's Data Safety and Monitoring Board proposed
creating a new stent branch comprised of only those patients receiving a longer
duration of anti-platelet therapy (APT), a change first implemented by Novoste
in November 1998 to address late stent thrombosis concerns. Patient recruitment
continued until September 1999, at which time 1,455 patients had been enrolled
into the Trial at 59 investigational sites in North America and Europe.
Data Presentation. On March 18, 2001, the Company announced the results of
-----------------
the Beta-Cath(TM) System Trial. While the primary clinical endpoint of the
overall Trial did not demonstrate a significant benefit of beta radiation when
the two branches of the Trial (balloon and stent) were combined, beta radiation
was shown to significantly reduce the risk of angiographic restenosis in the
lesion for patients undergoing either balloon angioplasty or stent implantation,
when compared to the placebo group. In the PTCA branch, restenosis in the lesion
segment was significantly reduced by 38% in the group receiving radiation versus
placebo. In addition, the effect of beta radiation on all clinical outcomes in
the PTCA branch demonstrated a strong positive trend. The results of the
Beta-Cath(TM) System Trial may, nevertheless, be insufficient to support an
application for pre-market approval in the U.S. to use our device following
balloon angioplasty or previously untreated (de novo) lesions.
The Trial was first analyzed by comparing the clinical outcomes of the total
radiation cohort (those receiving either PTCA or a stent with extended APT) to
the overall placebo group. Then the data was analyzed by reviewing the PTCA and
the stent branches individually. The clinical data from the total combination of
PTCA and stent patients is as follows.
Beta-Cath(TM) System Trial Clinical Data
--------------------------
Combined Group: PTCA + Stent (Extended APT) Branches
- ----------------------------------------------------------------------------
Beta Placebo
Radiation Control Percent
Clinical Outcomes (N=492) (N=464) Difference
- ----------------------------------------------------------------------------
Target Lesion Revascularization (TLR) 13.7% 15.4% (12%)
- ----------------------------------------------------------------------------
Target Vessel Revascularization (TVR) 15.6% 17.4% (10%)
- ----------------------------------------------------------------------------
Major Adverse Cardiac Events (MACE) 18.7% 20.6% (9%)
- ----------------------------------------------------------------------------
8
In this combined group of PTCA and stent patients, those who received beta
radiation exhibited modest improvements in their clinical endpoints, although
not statistically significant. Upon analysis of the two Trial branches as
discussed below, it was clear that patients in the PTCA branch clinically
benefited more from radiation than did those in the Stent branch, thereby
leading to a less pronounced effect when the two branches were combined.
Beta-Cath(TM) System Trial Data: PTCA Branch
-----------------
- ----------------------------------------------------------------------------
Beta Placebo
Radiation Control Percent
Angiographic Results (N=264) (N=240) Difference
- ----------------------------------------------------------------------------
Restenosis Rate:
- ----------------------------------------------------------------------------
Lesion Segment 21.4% 34.3% (38%)
- ----------------------------------------------------------------------------
Analysis Segment 31.0% 36.0% (14%)
- ----------------------------------------------------------------------------
Clinical Outcomes
- ----------------------------------------------------------------------------
Target Lesion Revascularization (TLR) 10.0% 15.3% (35%)
- ----------------------------------------------------------------------------
Target Vessel Revascularization (TVR) 12.3% 17.0% (28%)
- ----------------------------------------------------------------------------
Major Adverse Cardiac Events (MACE) 14.2% 20.4% (30%)
- ----------------------------------------------------------------------------
In the PTCA branch, restenosis in the legion segment was significantly
reduced by 38% in the group receiving radiation versus placebo. In addition, the
effect of beta radiation on all clinical outcomes in the PTCA branch
demonstrated a strong positive trend.
Beta-Cath(TM) System Trial Data: Stent w/extended APT Branch
-----------------
- ----------------------------------------------------------------------------
Beta Placebo
Radiation Control Percent
Angiographic Results (N=228) (N=224) Difference
- ----------------------------------------------------------------------------
Restenosis Rate:
- ----------------------------------------------------------------------------
Lesion Segment 21.1% 33.0% (36%)
- ----------------------------------------------------------------------------
Analysis Segment 44.9% 35.3% 21%
- ----------------------------------------------------------------------------
Clinical Outcomes
- ----------------------------------------------------------------------------
Late Stent Thrombosis 1.3% 1.3% 0%
- ----------------------------------------------------------------------------
Target Lesion Revascularization (TLR) 18.0% 15.5% 14%
- ----------------------------------------------------------------------------
Target Vessel Revascularization (TVR) 19.4% 17.7% 9%
- ----------------------------------------------------------------------------
Major Adverse Cardiac Events (MACE) 23.9% 20.8% 13%
- ----------------------------------------------------------------------------
9
In the Stent branch, angiographic restenosis in the lesion was also reduced
significantly (by 36%) as in the PTCA branch; however, radiation did not improve
restenosis in the much longer analysis segment. This was likely due to
"geographic miss", the mismatch of the radiation source train relative to the
placement of the stent, which was implanted after the radiation catheter was
removed. In reviewing the clinical endpoints of the Stent branch, the data did
not show a beneficial effect of radiation on improving outcomes. The incidence
of late thrombosis, however, was the same (1.3%) in both the radiation and the
placebo groups, indicating that the extended antiplatelet therapy resolved the
problems of thrombosis observed in the original stent branch.
The foregoing trials were administered by our clinical and regulatory staff
of eleven people. We used consultants to monitor the clinical sites and to
assist in training. We also have engaged an independent contract research
organization and consultants to compile data from the trials and to perform
statistical and reimbursement analyses.
10
PRODUCT DEVELOPMENT
Research and development activities are performed by a 22-person product-
development team. We have also retained consultants to assist in many research
and development activities, including design and manufacture of the Beta-
Cath(TM) System, monitoring the clinical trials relating to the Beta-Cath(TM)
System and advising in key aspects of radiation health physics and dosimetry.
The focus of our current development efforts is the design of future
generation components of the Beta-Cath(TM) System. We intend to introduce a
delivery catheter with a smaller outer diameter so that arteries smaller than
2.7mm can be treated, thereby expanding our market opportunity into smaller
coronary vessels. Likewise, we anticipate modifying the transfer device to have
a more ergonomic design and to incorporate additional features. Additional
future development efforts will focus on modifying the Beta-Cath(TM) System for
use in peripheral applications, such as arterial-venous shunts and the femoral
arteries. There can be no assurance that we will be successful in developing
these or other products.
Research and development expenses for the years ended December 31, 2000,
1999, and 1998 were approximately $ 17.1 million, $22.9 million and $21.1
million, respectively.
SALES AND MARKETING
We have recruited a qualified and experienced field sales, sales management
and marketing organization and are selling our products directly in the United
States through that organization. At year end, this organization totaled 60
employees, with another 10 being recruited to support the continued domestic
market introduction.
The Company is directing its sales and marketing efforts at prominent
domestic and international cardiac catheterization laboratories that perform the
majority of the interventional cardiology procedures. The Company believes that
prominent cardiac cath labs are generally more likely to keep abreast of and
utilize new technologies such as the Beta-Cath(TM) System for diagnosing and
treating restenosis. After the Company establishes a presence in major medical
centers housing such cardiac cath labs, it then intends to broaden its sales and
marketing efforts to include the growing number of smaller, community-based
cardiac cath labs. The Company's sales and marketing strategy includes
developing and maintaining a close working relationship with its customers in
order to assess and satisfy their needs for products and services. The Company
meets with clinicians both in the United States and Europe periodically to share
ideas regarding the marketplace, existing products, products under development
and existing or proposed research projects.
As part of our strategy to increase the awareness of and acceptance of
vascular brachytherapy and the Beta-Cath(TM) System in cardiac cath labs, the
Company will focus on developing peer reviewed journal articles authored by
leading experts in interventional cardiology, sponsoring publication of papers
based on research covering the performance and benefits of the Beta-Cath(TM)
System and conducting informational seminars.
Our direct sales activities target all of the medical specialists involved
in vascular brachytherapy: cardiologists, radiation therapists and medical
physicists, which results in a lengthy sales effort. To reach each of these
groups, we are using a multidisciplinary sales force consisting of experienced
medical device salespeople, clinical specialists with nursing experience in
cardiology, and medical physicists experienced in obtaining licenses for new
radioactive medical products.
MANUFACTURING, SOURCES OF SUPPLY AND SCALE-UP
Our manufacturing operations are required to comply with the FDA's quality
systems regulations, which included an inspection of our manufacturing
facilities prior to pre-market approval. In addition, certain international
markets have quality assurance and manufacturing requirements that may be more
or less rigorous than those in the United States. Specifically, we are subject
to the compliance requirements of ISO 9001 certification and CE mark directives
in order to produce products for sale in Europe. We received ISO 9001/EN 46001
certification from our European notified body in April 1998. We are subject to
periodic inspections by regulatory authorities to ensure such compliance. See
"Government Regulation." We conduct quality audits of suppliers and we are
establishing a vendor certification program. All suppliers of components must
also be in compliance with Novoste's and the FDA's quality systems regulations.
11
Single-Source Supplier of Beta Radiation Source Trains
- ------------------------------------------------------
We have obtained all of our requirements for our beta radioactive sources
to date pursuant to an agreement with a single supplier, Bebig Isotopentechnik
und Umweltdiagnostik GmbH, a German corporation and a related option agreement
to purchase assets.
Our supply agreement with Bebig had an initial term ending in November 2000
which has been extended to November, 2001. Under the supply agreement, Bebig has
agreed not to sell, lease, license or otherwise transfer radioactive Strontium
90 sources to any other party for use in treatment of restenosis. We, in turn,
have agreed not to purchase, lease, or otherwise acquire directly or indirectly
more than 30% of our annual requirement for radioactive sources of "like"
isotope for use in the treatment of restenosis from any other party. Bebig is
required to comply with various regulatory requirements with respect to the
supply of radiation sources. Bebig has agreed to manufacture radioactive sources
at an agreed-upon base price. Bebig also has agreed to grant us an exclusive,
worldwide, fully-paid license to use inventions, improvements or discoveries
Bebig may make relating to vascular brachytherapy devices. We, in turn, have
agreed to grant a similar license to Bebig relating to any inventions,
improvements or discoveries we may make relating to sealed radioactive sources,
provided Bebig does not use those inventions, improvements or discoveries for
vascular brachytherapy applications. In view of the technical expertise and
capital investment required to manufacture the radioactive sources and the
limited number of manufacturers of Strontium 90, it would be difficult to find
an alternate source of supply without significant lead time. Our business,
results of operations and financial condition could be materially adversely
affected by Bebig's failure to provide us with beta isotopes on a timely basis
during the term of the agreement or by our inability to obtain an alternative
source of supply on a timely basis and on terms satisfactory to us following any
termination of the agreement. In addition, portions of the process used to
manufacture the materials may be proprietary to Bebig.
On July 23, 1998, we executed a further amendment to our agreements with
Bebig, whereby we received a lien on all tangible and intangible assets used by
Bebig in the design and manufacture of the Strontium 90 radioactive sources. In
addition, under that amendment, we have exercised our option to purchase the
tangible assets, and obtain a fully paid license to all intellectual property
used in the manufacture of the radioactive sources, for $4,019,400. The purchase
price is payable in the form of a license fee payable on a per train basis over
four years commencing in 1998, though we have no obligation to purchase any
units after the expiration or termination of the supply agreement. These license
payments aggregated, $1,487,000 and $421,900 in 2000 and 1999, respectively, and
have been recorded as inventory costs. In the event we do not pay the full
purchase price for the assets before September 1, 2002, Bebig will have no
obligation to make any of its know-how or technology available to us or any
other source of supply. We are also obligated to pay Bebig the cost (not to
exceed 500,000 DM, or approximately $300,000) to decontaminate its Strontium 90
line assets under certain circumstances.
On October 14, 1999 the Company signed a development and manufacturing
supply agreement with AEA Technologies QSA GmbH for a second source of
radioactive supply and for the development of a smaller diameter radiation
source. The agreement provides for the construction of a production line which
is expected to be finished in two phases. The first phase was completed in
February 2001 and the second phase is expected to be completed in August 2001.
The completion of each phase allows the Company to scale up production as demand
requires. The cost of this production line is estimated at $4,000,000 and will
be paid by us as construction progresses. In addition, the agreement provides
for joint ownership of all intellectual property arising from the development
work and that AEA may manufacture vascular brachytherapy sources only for us.
The development of the smaller diameter source may not be successfully
completed, the new production line may not be completed on time or on budget,
and the smaller diameter source may not be manufacturable in commercial
quantities.
Supply of Other Components by Third Parties
- -------------------------------------------
We currently rely on third party manufacturers for the supply of the hand-
held transfer device and other components of our Beta-Cath(TM) System. The
supply of these components requires a long lead time. In addition, we could not
establish quickly additional or replacement suppliers or internal manufacturing
capabilities for these components. An existing vendor's failure to supply
components in a timely manner or our inability to obtain these components on a
timely basis from another supplier could have a material adverse effect on our
ability to manufacture the Beta-Cath(TM) System and, therefore, on our ability
to market the Beta-Cath(TM) System.
PATENTS AND PROPRIETARY TECHNOLOGY
Our policy is to protect our proprietary position by, among other methods,
filing United States and foreign patent applications. On November 4, 1997 we
were issued United States Patent No. 5,683,345, on May 4, 1999 we received
United States Patent No. 5,899,882 (which is jointly owned by us and Emory
University) and on January 11, 2000 we received United States Patent No.
6,013,020, all related to the Beta Cath(TM) System. We also have several
additional United States applications pending covering aspects
12
of our Beta-Cath(TM) System. The United States Patent and Trademark Office has
indicated that certain claims pending in another United States application are
allowable. With respect to the above identified United States Patents and our
other pending United States patent applications, we have filed, or will file in
due course, counterpart applications in the European Patent Office and certain
other countries.
Like other firms that engage in the development of medical devices, we must
address issues and risks relating to patents and trade secrets. United States
Patent No. 5,683,345 may not offer any protection to us because competitors may
be able to design functionally equivalent devices that do not infringe this
patent. It may also be reexamined, invalidated or circumvented. In addition,
claims under our other pending applications may not be allowed, or if allowed,
may not offer any protection or may be reexamined, invalidated or circumvented.
In addition, competitors may have or may obtain patents that will prevent, limit
or interfere with our ability to make, use or sell our products in either the
United States or international markets.
We received a letter from NeoCardia, L.L.C., dated July 7, 1995, in
which NeoCardia notified us that it was the exclusive licensee of United States
Patent No. 5,199,939, or the Dake patent, and requested that we confirm that our
products did not infringe the claims of the Dake patent. On August 22, 1995 our
patent counsel responded on our behalf that we did not infringe the Dake patent.
The United States Patent and Trademark Office later reexamined the Dake
patent. In the reexamination proceeding some of the patent claims were amended
and new claims were added. We have concluded, based upon advice of patent
counsel, that our Beta-Cath(TM) System does not infringe any claim of the Dake
patent as reexamined.
In May 1997 Guidant acquired NeoCardia together with the rights under the
Dake patent. Guidant is attempting to develop and commercialize products that
may compete with the Beta-Cath(TM) System and has significantly greater capital
resources than the Company. Guidant may sue for patent infringement in an
attempt to obtain damages from us and/or injunctive relief restraining us from
commercializing the Beta-Cath(TM) System in the United States. While the Company
does not believe such an action would have merit, if Guidant were successful in
any such litigation, we might be required to obtain a license from Guidant under
the Dake patent to market the Beta-Cath(TM) System in the United States, if such
license were available, or be prohibited from selling the Beta-Cath(TM) System
in the United States. Any of these actions could have a material adverse effect
on our business, financial condition and results of operations, or could result
in cessation of our business.
We have two versions of our delivery catheter: a "rapid exchange" catheter
and an "over the wire" catheter. As a result of certain United States patents
held by other device manufacturers covering "rapid exchange" catheters, we
currently intend to sell the "over the wire" version of our delivery catheter in
the United States. If further investigation reveals that we may sell a "rapid
exchange" version in the United States without infringing the valid patent
rights of others, we might decide to do so in the future. However, we cannot
assure that we will be able to sell a "rapid exchange" version in the United
States without a license of third party patent rights or that such a license
would be available to us on favorable terms or at all.
The medical device industry has been characterized by extensive litigation
regarding patents and other intellectual property rights. Companies in the
medical device industry have employed intellectual property litigation to gain a
competitive advantage. There can be no assurance that we will not become subject
to patent-infringement claims or litigation or interference proceedings declared
by the United States Patent and Trademark Office to determine the priority of
inventions. The defense and prosecution of intellectual property suits, or
interference proceedings and related legal and administrative proceedings are
both costly and time-consuming. Litigation may be necessary to enforce our
patents, to protect our trade secrets or know-how or to determine the
enforceability, scope and validity of the proprietary rights of others. Any
litigation or interference proceedings will result in substantial expense to us
and significant diversion of effort by our technical and management personnel.
An adverse determination in litigation or interference proceedings to which we
may become a party could subject us to significant liabilities to third parties,
require us to seek licenses from third parties, require us to redesign our
products or processes to avoid infringement or prevent us from selling our
products in certain markets, if at all. Although patent and intellectual
property disputes regarding medical devices have often been settled through
licensing or similar arrangements, costs associated with such arrangements may
be substantial and could include significant ongoing royalties. Furthermore,
there can be no assurance that the necessary licenses would be available to us
on satisfactory terms, if at all, or that we could redesign our products or
processes to avoid infringement. Any adverse determination in a judicial or
administrative proceeding or failure to obtain necessary licenses could prevent
us from manufacturing and selling our products, which would have a material
adverse effect on our business, financial condition and results of operations.
Patent applications in the United States and patent applications in foreign
countries are maintained in secrecy for a period after the earliest claimed
priority date. Publication of discoveries in the scientific or patent literature
tends to lag behind actual discoveries and
13
the filing of related patent applications. Patents issued and patent
applications filed relating to medical devices are numerous. Accordingly, there
can be no assurance that current and potential competitors, many of which have
substantial resources and have made substantial investments in competing
technologies, or other third parties have not or will not file applications for,
or have not or will not receive, patents and will not obtain additional
proprietary rights relating to products made, used or sold or processes used or
proposed to be used by us.
We have developed certain of our patent and proprietary rights relating to
the Beta-Cath(TM) System in conjunction with Emory University Hospital, a leader
in the research of intravascular radiation therapy. To obtain the exclusive
rights to commercialize the Beta-Cath(TM) System for the treatment of
restenosis, we entered into a license agreement with Emory. Under this
agreement, Emory assigned to us all of Emory's rights to one United States
patent application and exclusively licensed to us its rights under another
United States application and related technology. Emory made no representation
or warranty with respect to its ownership of the assigned patent application,
and made only limited representations as to its ownership of the licensed patent
application and related technology. Under the agreement Emory will be entitled
to royalty payments based upon net sales of the Beta-Cath(TM) System. The term
of the agreement runs through the later of (i) the date the last patent covered
by the agreement expires or (ii) January 2016 (unless earlier terminated as
provided in the agreement). Any inventions developed jointly by our personnel
and Emory during the term of the license agreement are owned jointly by Emory
and us. If Emory terminated the agreement as a result of our failure to pay such
royalties or any other breach of our obligations under such agreement, our
rights to use jointly owned patents (including the United States Patent No.
5,899,882) would become non-exclusive and we would have no rights to use future
patents owned exclusively by Emory. In addition, if we breach our obligations
under the license agreement, we could be required by Emory to cooperate in
licensing the pending jointly-owned United States patent application and our
foreign counterparts to third parties so that they would be able to
commercialize and sell the Beta-Cath(TM) System.
All of the physicians on staff at Emory who were involved in the
development of the Beta-Cath(TM) System, including Spencer B. King III, M.D.,
have assigned their rights in the technology, if any, to Emory and/or us. In
addition, we have entered into a license agreement with Dr. King. Under the
terms of this agreement, Dr. King is entitled to receive a royalty on the net
sales of the Beta-Cath(TM) System (excluding consideration paid for the
radioactive isotope), subject to a maximum of $5,000,000.
We employ a full time manager of intellectual property to prepare invention
records and to coordinate the prosecution of new intellectual property. We
typically obtain confidentiality and invention assignment agreements in
connection with employment, consulting and advisory relationships. These
agreements generally provide that all confidential information developed or made
known to the individual by us during the course of the individual's relationship
with us, is to be kept confidential and not disclosed to third parties, except
in specific circumstances. There can be no assurance, however, that these
agreements will provide meaningful protection or adequate remedies for us in the
event of unauthorized use, transfer or disclosure of such information or
inventions.
Furthermore, our competitors may independently develop substantially equivalent
proprietary information and techniques, or otherwise gain access to our
proprietary technology, and we may not be able to meaningfully protect our
rights in unpatented proprietary technology.
COMPETITION; RAPID TECHNOLOGICAL CHANGE
Competition in the medical device industry, and specifically the markets
for cardiovascular devices, is intense and characterized by extensive research
and development efforts and rapidly advancing technology. New developments in
technology could render vascular brachytherapy generally or the Beta-Cath(TM)
System in particular noncompetitive or obsolete.
Vascular brachytherapy may compete with other treatment methods designed to
improve outcomes from coronary artery procedures that are well established in
the medical community, such as coronary stents. Stents are the predominant
treatment currently utilized to reduce the incidence of coronary restenosis
following PTCA and were used in approximately 75% of all PTCA procedures
performed worldwide in 2000. Manufacturers of stents include Johnson & Johnson,
Medtronic, Inc., Guidant Corporation and Boston Scientific Corporation. Stent
manufacturers often sell many products used in the cardiac catheterization labs,
commonly referred to as cath labs, and as discussed below, certain of these
companies are developing vascular brachytherapy devices.
Also on November 3, 2000, the FDA approved Johnson & Johnson's
CHECKMATE(TM) System, a gamma radiation vascular brachytherapy device. Johnson &
Johnson will compete directly with Novoste for market acceptance of vascular
brachytherapy and has substantially greater capital resources and greater
resources and experience at introducing new products than does Novoste. We may
not be able to compete effectively against Johnson & Johnson.
14
Many of these same companies and others are researching coatings and
treatments to coronary stents that could reduce restenosis and would possibly be
more acceptable to a medical community already experienced at using stents.
Recently, results from early non-randomized trials were reported as eliminating
restenosis. Extensive clinical trials will need to be completed in order to
confirm these results, however, positive information from these trials could
have a negative impact on the ultimate acceptability of vascular brachytherapy
and the Company's stock price.
Many of our competitors and potential competitors have substantially
greater capital resources than we do and also have greater resources and
expertise in the area of research and development, obtaining regulatory
approvals, manufacturing and marketing. Our competitors and potential
competitors may succeed in developing, marketing and distributing technologies
and products that are more effective than those we will develop and market or
that would render our technology and products obsolete or noncompetitive.
Additionally, many of the competitors have the capability to bundle a wide
variety of products in sales to cath labs. We may be unable to compete
effectively against such competitors and other potential competitors in terms of
manufacturing, marketing, distribution, sales and servicing.
Any product we develop that gains regulatory clearance or approval will
have to compete for market acceptance and market share. An important factor in
such competition may be the timing of market introduction of competitive
products. Accordingly, we expect the relative speed with which we can develop
products, gain regulatory approval and reimbursement acceptance and supply
commercial quantities of the product to the market to be an important
competitive factor. In addition, we believe that the primary competitive factors
for products addressing restenosis include safety, efficacy, and ease of use,
reliability, and suitability for use in cath labs, service and price. We also
believe that physician relationships, especially relationships with leaders in
the interventional cardiology and radiation oncology communities, are important
competitive factors.
GOVERNMENT REGULATION
United States
- -------------
Our Beta-Cath(TM) System is regulated in the United States as a medical
device. As such, we are subject to extensive regulation by the FDA, by other
federal, state and local authorities and by foreign governments. The FDA
regulates the clinical testing, manufacture, packaging, labeling, storage,
distribution and promotion of medical devices. Noncompliance with applicable
requirements can result in, among other things, fines, injunctions, civil
penalties, recall or seizure of products, total or partial suspension of
production, failure of the government to grant pre-market clearance or pre-
market approval for devices, withdrawal of marketing approvals, a recommendation
by the FDA that we not be permitted to enter into government contracts, and
criminal prosecution. The FDA also has the authority to request repair,
replacement or refund of the cost of any device manufactured or distributed.
In the United States, medical devices are classified into one of three
classes (Class I, II or III) on the basis of the controls deemed necessary by
the FDA to reasonably assure their safety and effectiveness. Under FDA
regulations Class I devices are subject to general controls (for example,
labeling, pre-market notification and adherence to good manufacturing practices
or quality systems regulations) and Class II devices are subject to general and
special controls (for example, performance standards, postmarket surveillance,
patient registries, and FDA guidelines). Class III is the most stringent
regulatory category for medical devices. Generally, Class III devices are those
that must receive pre-market approval by the FDA after evaluation of their
safety and effectiveness (for example, life-sustaining, life-supporting or
implantable devices, or new devices that have not been found substantially
equivalent to other Class II legally marketed devices). The Beta-Cath(TM) System
is a Class III device, which required the FDA's pre-market approval prior to its
commercialization, which occurred November 2000.
A pre-market approval application must be supported by valid scientific
evidence, which typically includes extensive data, including preclinical and
human clinical trial data to demonstrate safety and effectiveness of the device.
If human clinical trials of a device are required and the device trial presents
a "significant risk," the sponsor of the trial, usually the manufacturer or the
distributor of the device, is required to file an investigational device
exemption application with the FDA and obtain FDA approval prior to commencing
human clinical trials. The investigational device exemption application must be
supported by data, typically including the results of animal and laboratory
testing. If the investigational device exemption application is approved by the
FDA and one or more appropriate Institutional Review Boards, or "IRBs," human
clinical trials may begin at a specific number of investigational sites with a
specific number of patients, as approved by the FDA.
The pre-market approval application must also contain the results of all
relevant bench tests, laboratory and animal studies, a complete description of
the device and its components, and a detailed description of the methods,
facilities and controls used to manufacture the device. In addition, the
submission should include the proposed labeling, advertising literature and
training methods (if required).
If the FDA's evaluation of the pre-market approval application is
favorable, the FDA will either issue an approval letter or an "approvable
letter," containing a number of conditions which must be satisfied in order to
secure the final approval of the pre-market approval application. When and if
those conditions have been fulfilled to the satisfaction of the FDA, the agency
will issue a letter approving a pre-market approval application authorizing
commercial marketing of the device for certain indications. If the FDA's
evaluation of the pre-market approval application or manufacturing facilities is
not favorable, the FDA will deny approval of the pre-market approval application
or issue a "not approvable letter." The FDA may also determine that additional
clinical trials are necessary, in which case approval of the pre-market approval
application could be delayed for several years while additional clinical trails
are conducted and submitted in an amendment to the pre-market approval
application.
On November 3, 2000, the FDA approved our pre-market approval (PMA)
application for the Beta-Cath(TM) System. This approval limits our ability to
promote the Beta-Cath(TM) System to use with patients who are being treated for
"in-stent" restenosis in a single coronary artery with a 30-millimeter radiation
source train. In order to market the Beta-Cath(TM) System with a 40-millimeter
radiation source train, we submitted a PMA supplement to the FDA on December 27,
2000 and included the data from our START 40 trial in order to demonstrate
safety and efficacy. The PMA supplement is currently under review with the FDA.
In order to market the Beta-Cath(TM) System for use with (1) further product
design enhancements, such as varying lengths of the radiation source train or
modifications to the catheter or (2) with a broader range of indications, we
will likely
15
be required to demonstrate to the FDA through additional clinical trials that
the Beta-Cath(TM) System is safe and effective with such product design
enhancement(s) or in treating a broader range of indications and the FDA must
approve a pre-market approval application, application amendment or application
supplement covering the product design enhancement(s) or the broader range of
indications for the device.
The process of obtaining a pre-market approval and other required
regulatory approvals can be expensive, uncertain and lengthy, and we may be
unsuccessful in obtaining approvals to market the Beta-Cath(TM) System for use
with (1) further product design enhancements, such as varying lengths of the
radiation source train or modifications to the catheter or (2) with a broader
range of indications. We do not anticipate pre-market approval for the
supplement application for the 40mm Beta-Cath(TM) System to treat in-stent
restenosis until the second quarter of 2001, if at all. The FDA may not act
favorably or quickly on any of our submissions to the FDA. We may encounter
significant difficulties and costs in our efforts to obtain additional FDA
approvals that could delay or preclude us from selling new products in the
United States. Furthermore, the FDA may request additional data or require that
we conduct further clinical studies, causing us to incur substantial cost and
delay. In addition, the FDA may impose strict labeling requirements, onerous
operator training requirements or other requirements as a condition of our pre-
market approval, any of which could limit our ability to market our systems.
Labeling and marketing activities are subject to scrutiny by the FDA and, in
certain circumstances, by the Federal Trade Commission. FDA enforcement policy
strictly prohibits the marketing of FDA cleared or approved medical devices for
unapproved uses, Further, if a company wishes to modify a product after FDA
approval of a pre-market approval, including any changes that could affect
safety or effectiveness, additional approvals will be required by the FDA. Such
changes include, but are not limited to: new indications for use, the use of a
different facility to manufacture, changes to process or package the device,
changes in vendors to supply components, changes in manufacturing methods,
changes in design specifications and certain labeling changes. Failure to
receive or delays in receipt of FDA approvals, including the need for additional
clinical trials or data as a prerequisite to approval, or any FDA conditions
that limit our ability to market our systems, could have a material adverse
effect on our business, financial condition and results of operations.
Any products we manufacture or distribute pursuant to FDA approvals are
subject to pervasive and continuing regulation by the FDA, including record-
keeping requirements and reporting of adverse experiences with the use of the
device. Device manufacturers are required to register their establishments and
list their devices with the FDA and certain state agencies, and are subject to
periodic inspections by the FDA and those state agencies. The Food, Drug and
Cosmetic Act requires device manufacturers to comply with good manufacturing
practices regulations. A new set of regulations, called the quality systems
regulations, went into effect June 1, 1997. The regulations require that medical
device manufacturers comply with various quality control requirements pertaining
to design controls, purchasing contracts, organization and personnel; device and
manufacturing process design; buildings, environmental control, cleaning and
sanitation; equipment and calibration of equipment; medical device components;
manufacturing specifications and processes; reprocessing of devices; labeling
and packaging; in-process and finished device inspection and acceptance; device
failure investigations; and recordkeeping requirements including compliance
files. The FDA enforces these requirements through periodic inspections of
medical device manufacturing facilities. In addition, a set of regulations known
as the medical device reporting regulations obligates manufacturers to inform
the FDA whenever information reasonably suggests that one of its devices may
have caused or contributed to a death or serious injury, or when one of its
devices malfunctions and, if the malfunction were to recur, the device would be
likely to cause or contribute to a death or serious injury.
Labeling and promotional activities are also subject to scrutiny by the
FDA. Among other things, labeling violates law if it is false or misleading in
any respect or it fails to contain adequate directions for use. Moreover, any
labeling claims that exceed the representations approved by the FDA will violate
the Food, Drug and Cosmetic Act.
Our product advertising is also subject to regulation by the Federal Trade
Commission under the Federal Trade Commission Act, which prohibits unfair
methods of competition and unfair or deceptive acts or practices in or affecting
commerce, including the dissemination of any false advertisement pertaining to
medical devices. Under the Federal Trade Commission's "substantiation doctrine,"
an advertiser is required to have a "reasonable basis" for all product claims at
the time claims are first used in advertising or other promotions.
Our business involves the import, export, manufacture, distribution, use
and storage of Strontium-90 (Strontium/Yttrium), the beta-emitting radioisotope
utilized in the Beta-Cath(TM) System 's radiation source train. Accordingly,
manufacture, distribution, use and disposal of the radioactive material used in
the Beta-Cath(TM) System in the United States will be subject to federal, state
and/or local rules relating to radioactive material. The State of Georgia
Department of Natural Resources (DNR) issued a sealed source and device
registration certificate for the Company's Beta-Cath(TM) System on August 4,
2000, allowing it to be listed on the Nuclear Regulatory Commission's Sealed
Source and Device Registry. The DNR authorized Novoste to commercially
distribute its radiation sources to licensed recipients in the United States
with the issuance of a license allowing the manufacturing and distribution of
the Beta-Cath(TM) System. In addition, we must comply with NRC, Georgia and
United States Department of Transportation regulations on the labeling and
packaging requirements for shipment of radiation sources to hospitals or other
users of the Beta-Cath(TM) System.
Hospitals in the United States are required to have radiation licenses to
hold, handle and use radiation. Many of the hospitals and/or physicians in the
United States will be required to amend their radiation licenses to include
Strontium-90 prior to receiving and using our Beta-Cath(TM) System. Depending on
the state that the hospital is located in, its license amendment will be
processed at the DNR in agreement states, or by the NRC. Obtaining any of the
foregoing radiation-related approvals and licenses can be complicated and time
consuming and may take longer in the NRC States (sixteen states). A significant
majority of the approved license amendments have been in Non-NRC states. If a
significant number of hospitals are delayed in obtaining any of the foregoing
approvals or any of those approvals are not obtained, our business, financial
condition and results of operations could be materially adversely affected.
We are also subject to numerous federal, state and local laws relating to
such matters as safe working conditions, manufacturing practices, environmental
protection, fire-hazard control and disposal of hazardous or potentially
hazardous substances. We may be required to incur significant costs to comply
with such laws and regulations now or in the future and such laws or regulations
could have a material adverse effect upon our ability to do business.
Changes in existing requirements or adoption of new requirements or
policies could adversely affect our ability to comply with regulatory
requirements. Our failure to comply with regulatory requirements could have a
material adverse effect on our business, financial condition or results of
operations. We may be required to incur significant costs to comply with laws
and regulations in the future and these laws and regulations could have a
material adverse effect upon our business, financial condition or results of
operations.
INTERNATIONAL
We qualified to apply CE marking to the Beta-Cath(TM) System in August
1998, which allows us to sell the device in the 18 countries of the European
Economic Area, or EEA, and Switzerland. Although the medical devices directive
is intended to ensure free movement within the EEA of medical devices that bear
the CE marking, many countries in the EEA have imposed additional requirements,
such as labeling in the national language and notification of placing the device
on the market. In addition, regulatory authorities in European countries can
demand evidence on which conformity assessments for CE-marked devices are based
and in certain circumstances can prohibit the marketing of products that bear
the CE marking. Many European countries maintain systems to control the purchase
and reimbursement of medical equipment under national health care programs, and
the CE marking does not affect these systems.
In order for us to market the Beta-Cath(TM) System in Japan and certain
other foreign jurisdictions, we must obtain and retain required regulatory
approvals and clearances and otherwise comply with extensive regulations
regarding safety and manufacturing processes and quality. These regulations,
including the requirements for approvals or clearance to market and the time
required for regulatory review, vary from country to country, and in some
instances within a country. We may not be able to obtain regulatory approvals in
such countries or may be required to incur significant costs in obtaining or
maintaining our foreign regulatory approvals. Delays in receipt of approvals to
market our products, failure to receive these approvals or future loss of
previously received approvals could have a material adverse effect on our
business, financial condition, and results of operations.
The time required to obtain approval for sale in foreign countries may be
longer or shorter than that required for FDA approval, and the requirements may
differ. The European Union has promulgated rules requiring that medical devices
placed on the market after June 14, 1998 bear CE marking, a legal symbol
attesting to compliance with the appropriate directive which, in our case, is
the medical devices directive. The Company's products have not received
regulatory approval in Japan nor have they been approved for government
reimbursement in Japan.
In addition, there are generally foreign regulatory barriers other than
pre-market approval (including separate regulations concerning the distribution,
use, handling and storage of radiation sources), and the export of devices must
be in compliance with FDA regulations. The distribution and use of the Beta-
Cath(TM) System outside the United States is subject to radiation regulatory
requirements that vary from country to country and sometimes vary within a given
country. Generally, each country has a national regulatory agency responsible
for regulating the safe practice and use of radiation in its jurisdiction. In
addition, each hospital desiring to use the Beta-Cath(TM) System is generally
required to amend its radiation license to hold, handle and use the Strontium 90
sources in our device. Generally, these licenses are specific to the amount and
type of radioactivity utilized. In addition, generally the use of a radiation
source by a physician, either for a diagnostic or therapeutic application, also
requires a license, which again is specific to the isotope and the clinical
application.
THIRD PARTY REIMBURSEMENT
We expect that our sales volumes and prices of our products will be heavily
dependent on the availability of reimbursement from third-party payors and that
individuals may not be willing or able to pay directly for the costs associated
with the use of our products.
16
Our products typically are purchased by clinics and hospitals, which bill
various third-party payors, such as governmental programs and private insurance
plans, for the healthcare services provided to their patients. Third-party
payors carefully review and increasingly challenge the prices charged for
medical products and services. Reimbursement rates from private companies vary
depending on the procedure performed, the third-party payor, the insurance plan,
and other factors. Medicare reimburses hospitals a prospectively determined
fixed amount for the costs associated with an in-patient hospitalization based
on the patient's discharge diagnosis, and reimburses physicians a prospectively
determined fixed amount based on the procedure performed, regardless of the
actual costs incurred by the hospital or physician in furnishing the care and
unrelated to the specific devices used in that procedure. Medical and other
third-party payors are increasingly scrutinizing whether to cover new products
and the level of reimbursement for covered products.
In international markets, market acceptance of the Beta-Cath(TM) System may
be dependent in part upon the availability of reimbursement within the
prevailing healthcare payment systems. Reimbursement systems vary significantly
by country, and by region within some countries, and reimbursement approvals
must be obtained on a country-by-country basis. In foreign markets,
reimbursement is obtained from a variety of sources, including government
sponsored healthcare and private health insurance plans. In some countries the
healthcare systems are centrally organized, but in most cases there is a degree
of regional autonomy either in deciding whether to pay for a particular
procedure or in setting the reimbursement level. The way in which new devices
enter the healthcare system depends on the system: there may be a national
appraisal process leading to a new procedure or product coding, or it may be a
local decision made by the relevant hospital department. The latter is
particularly the case where a global payment is made that does not detail
specific technologies used in the treatment of a patient. In most foreign
countries there are also private insurance plans that may offer reimbursement
for alternative therapies. Although not as prevalent as in the United States,
managed care is gaining prevalence in certain European countries. We will seek
international reimbursement approvals, although there can be no assurance that
any such approvals will be obtained in a timely manner or at all. Failure to
receive international reimbursement approvals could have an adverse effect on
market acceptance of our products in the international markets in which such
approvals are sought.
We believe that reimbursement in the future will be subject to increased
restrictions such as those described above, both in the United States and in
foreign markets. We believe that the overall escalating cost of medical products
and services has led to and will continue to lead to increased pressures on the
health care industry, both foreign and domestic, to reduce the cost of products
and services, including products we offer. In the United States or foreign
markets third-party reimbursement and coverage may not be available or adequate,
current reimbursement amounts may be decreased in the future and future
legislation, regulation, or reimbursement policies of third-party payors could
have a material adverse affect on the demand for our products or our ability to
sell our products on a profitable basis, particularly if our system is more
expensive than competing products or procedures. If third-party payor coverage
or reimbursement is unavailable or inadequate, our business, financial
condition, and results of operations could be materially adversely affected.
PRODUCT LIABILITY AND INSURANCE
Our business entails the risk of product liability claims. Although we have
not experienced any product liability claims to date, such claims could be
asserted and we may not have sufficient resources to satisfy any liability
resulting from such claims. We maintain product liability insurance with
coverage of an annual aggregate maximum of $8 million. Product liability claims
could exceed such insurance coverage limits, such insurance may not continue to
be available on commercially reasonable terms or at all, and a product liability
claim could have a material adverse affect on our business, financial condition
or results of operations.
EMPLOYEES AND CONSULTANTS
As of December 31, 2000 we directly employed 236 full-time individuals. Most
of our employees have prior experience with medical device or pharmaceutical
companies. We believe that we maintain good relations with our employees. None
of our employees is represented by a union or covered by a collective bargaining
agreement. Our success will depend in large part upon our ability to attract and
retain qualified employees. We face competition in this regard from other
companies, research and academic institutions and other organizations.
We maintain continuing relationships with a number of independent
consultants that have contributed to the development of our products and work on
specific development projects. These relationships are integral to our continued
success and the generation of new products from the research and development
departments.
ADDITIONAL RISK FACTORS
17
DEPENDENCE ON THE SUCCESSFUL DEVELOPMENT AND COMMERCIALIZATION OF THE BETA-CATH
SYSTEM
We have just recently begun to commercialize the Beta-Cath(TM) System in the
United States and our distribution system in Europe and certain Asian countries
are still being developed. We anticipate that for the foreseeable future we will
be solely dependent on the successful development and commercialization of the
Beta-Cath(TM) System. Our failure to continue commercialization of the
Beta-Cath(TM) System would have a material adverse effect on our business,
financial condition and results of operations.
The Beta-Cath(TM) System received FDA approval for the 30-millimeter system
on November 3, 2000; however, we may be unable to:
- manufacture the Beta-Cath(TM) System in commercial quantities at
acceptable costs;
- gain any significant degree of market acceptance of the Beta-Cath(TM)
System among physicians, patients and/or health care payors;
- broaden the Beta-Cath(TM) system marketability by obtaining approval
for additional applications of our product; or
- demonstrate that the Beta-Cath(TM) System is an attractive and
cost-effective alternative or complement to other procedures, including
coronary stents, competing vascular brachytherapy devices, or other
competitive technologies.
Because the Beta-Cath(TM) System is our sole near-term product focus, we
could be required to cease operations if it is not successfully commercialized.
LIMITED OPERATING HISTORY; HISTORY OF LOSSES AND EXPECTATION OF FUTURE LOSSES
THROUGH AT LEAST THE YEAR 2001
We have a limited history of operations. Since our inception in May 1992, we
have been primarily engaged in developing and testing our Beta-Cath(TM) System.
We have generated only limited revenue and do not have experience in
manufacturing, marketing or selling our products in quantities necessary for
achieving profitability.
At December 31, 2000 we had accumulated a deficit of approximately $116.3
million since our inception in 1992. The commercialization of the Beta-Cath(TM)
System and other new products, if any, will require substantial additional
development, clinical, regulatory, manufacturing, sales and marketing and other
expenditures. We expect our operating losses to continue through at least 2001
as we continue to expand our product development, clinical trials and marketing
efforts. We may never:
- achieve commercial success in the sale of the Beta-Cath(TM) System or
any other product in any countries in which we have received the
necessary governmental approvals to market these products; or
- achieve or sustain profitability.
NO ASSURANCE OF REGULATORY APPROVALS
United States Pre-Market Approvals.
- -----------------------------------
On November 3, 2000, we received marketing approval from the FDA for the
Beta-Cath(TM) System. This approval limits our ability to promote the Beta-
Cath(TM) System for use with patients who are being treated for "in-stent"
restenosis in a single coronary artery with a 30-millimeter radiation source
train. In order to market the Beth-Cath(TM) System with a 40-millimeter
radiation source train, we will likely be required to demonstrate to the FDA
through the START 40 Trial that the Beth-Cath(TM) System with the longer source
train is safe and effective. In order to market the Beta-Cath(TM) System for a
broader range of patients, we may seek to expand the indications for which the
Beta-Cath(TM) System can be marketed to, for example, patients undergoing
balloon angioplasty of previously untreated (de novo) lesions.
18
In order to market the Beta-Cath(TM) System for use with (1) further product
design enhancements, such as varying lengths of the radiation source train or
modifications to the catheter or (2) with a broader range of indications,
including stand alone balloon angioplasty or previously untreated (de novo)
lesions we will likely be required to demonstrate to the FDA through additional
clinical trials that the Beta-Cath(TM) System is safe and effective with such
product design enhancement(s) or in treating a broader range of indications and
the FDA must approve a pre-market approval application, application amendment or
application supplement covering the product design enhancement(s) or the broader
range of indications for the device. Even if we were to receive FDA approval
based on the results of the Beta-Cath(TM) System Trial, we would be limited
under that approval to promoting the Beta-Cath(TM) System for use with patients
who are being treated for one lesion in a single coronary artery following
stand-alone balloon angioplasty.
Foreign Pre-Market Approvals.
- -----------------------------
Sales of the Beta-Cath(TM) System outside the United States are subject to
regulatory requirements that vary widely from country to country but generally
include pre-marketing governmental approval. The time required to obtain
approval for sale in foreign countries may be longer or shorter than required
for FDA approval, and the requirements for the conduct of clinical trials,
marketing authorization, pricing and reimbursement differ from those in the
United States. Moreover, the export of medical devices from the United States
must be in compliance with FDA regulations. In August 1998 we qualified to apply
CE marking to the Beta-Cath(TM) System, a requirement necessary to sell our
device in most of Western Europe. We are subject to continuing audit and
reporting requirements related to this marking. We may be delayed or precluded
from marketing the Beta-Cath(TM) System in other foreign countries. Foreign pre-
market and other regulatory approvals of the Beta-Cath(TM) System, if granted,
may include significant limitations on the indicated uses for which the device
may be marketed.
Approvals to Use, Handle and Transfer Radioactive Materials.
- ------------------------------------------------------------
Our business involves the import, export, manufacture, distribution, use and
storage of Strontium-90 (Strontium/Yttrium), the beta-emitting radioisotope
utilized in the Beta-Cath(TM) System 's radiation source train. Accordingly,
manufacture, distribution, use and disposal of the radioactive material used in
the Beta-Cath(TM) System in the United States will be subject to federal, state
and/or local rules relating to radioactive material. Recently, the State of
Georgia Department of Natural Resources (DNR) issued a sealed source and device
registration certificate for the Company's Beta-Cath(TM) System, allowing it to
be listed on the Nuclear Regulatory Commission's Sealed Source and Device
Registry. The Company anticipates that the DNR will authorize Novoste to
commercially distribute our radiation sources to licensed recipients in the
United States. In addition, we must comply with NRC, Georgia and United States
Department of Transportation regulations on the labeling and packaging
requirements for shipment of radiation sources to hospitals or other users of
the Beta-Cath(TM) System. Further, hospitals and/or physicians in the United
States may be required to amend their radiation licenses to hold, handle and use
Strontium-90 prior to receiving and using our Beta-Cath(TM) System.
LIMITED MANUFACTURING EXPERIENCE; SCALE-UP RISK
To date, we have not yet successfully commercialized the Beta-Cath(TM)
System, and our manufacturing activities have consisted of producing small
quantities of our products for use in clinical trials and our initial product
launch in Europe and the United States. To achieve profitability, the Beta-
Cath(TM) System must be manufactured in commercial quantities in compliance with
regulatory requirements and at acceptable costs. Production in commercial
quantities will require us to expand our manufacturing capabilities and to hire
and train additional personnel. We have no experience in manufacturing our
products in commercial quantities. We may encounter difficulties in scaling up
production, including problems involving production yields, quality control and
assurance, component supply and shortages of qualified personnel. Difficulties
encountered in manufacturing scale up could have a material adverse effect on
our business, financial condition and results of operations. We cannot assure
that future manufacturing difficulties, which could have a material adverse
effect on our business, financial condition and results of operations, will not
occur.
DEPENDENCE ON KEY PERSONNEL
Our business and future operating results depend in significant part upon
the continued contributions of our key technical personnel and senior
management, many of whom would be difficult to replace. Our business and future
operating results also depend in significant part upon our ability to attract
and retain qualified management, manufacturing, technical, marketing, sales and
support personnel for our operations. Competition for such personnel is intense,
and we may not succeed in attracting or retaining such personnel. The loss of
key employees, the failure of any key employee to perform adequately or our
inability to attract and retain skilled employees, as needed, could materially
adversely affect our business, financial condition and results of operations.
19
ISSUANCE OF PREFERRED STOCK MAY ADVERSELY AFFECT RIGHTS OF COMMON SHAREHOLDERS
OR DISCOURAGE A TAKEOVER
Under our amended and restated articles of incorporation, our board of
directors has the authority to issue up to 5,000,000 shares of preferred stock
and to determine the price, rights, preferences and privileges of those shares
without any further vote or action by our shareholders. The rights of the
holders of common stock will be subject to, and may be adversely affected by,
the rights of the holders of any shares of preferred stock that may be issued in
the future.
In October 1996 our board of directors authorized 1,000,000 shares of Series
A Participating Preferred Stock in connection with its adoption of a shareholder
rights plan, under which we issued rights to purchase Series A Participating
Preferred Stock to holders of the common stock. Upon certain triggering events,
such rights become exercisable to purchase common stock (or, in the discretion
of our board of directors, Series A Participating Preferred Stock) at a price
substantially discounted from the then current market price of the common stock.
Our shareholder rights plan could generally discourage a merger or tender offer
involving our securities that is not approved by our board of directors by
increasing the cost of effecting any such transaction and, accordingly, could
have an adverse impact on shareholders who might want to vote in favor of such
merger or participate in such tender offer.
While we have no present intention to authorize any additional series of
preferred stock, such issuance, while providing desirable flexibility in
connection with possible acquisitions and other corporate purposes, could also
have the effect of making it more difficult for a third party to acquire a
majority of our outstanding voting stock. The preferred stock may have other
rights, including economic rights senior to the common stock, and, as a result,
the issuance thereof could have a material adverse effect on The market value of
the common stock.
OTHER PROVISIONS DISCOURAGING A TAKEOVER
The amended and restated articles of incorporation provide for a classified
board of directors, the existence of which could discourage attempts to acquire
us. Furthermore, we are subject to the anti-takeover provisions of the Florida
Business Corporation Act, the application of which would also have the effect of
delaying or preventing a merger, takeover or other change of control of the
Company and therefore could discourage attempts to acquire the Company.
PRICE VOLATILITY AND FLUCTUATIONS IN OPERATING RESULTS
The market price of our common stock could decline below the public offering
price. Specific factors relating to our business or broad market fluctuations
may materially adversely affect the market price of our common stock. The
trading price of our common stock could be subject to wide fluctuations in
response to quarter-to-quarter variations in operating results, announcements of
technological innovations, new products or clinical data announced by us or our
competitors, governmental regulatory action, developments with respect to
patents or proprietary rights, general conditions in the medical device or
cardiovascular device industries, changes in earnings estimates by securities
analysts, or other events or factors, many of which are beyond our control. In
addition, the stock market has experienced extreme price and volume
fluctuations, which have particularly affected the market prices of many medical
device companies and which have often been unrelated to the operating
performance of such companies. Our revenue or operating results in future
quarters may be below the expectations of securities analysts and investors. In
such an event, the price of our common stock would likely decline, perhaps
substantially. During the twelve month period ended March 30, 2001, the
closing price of our common stock ranged from a high of $61.00 per share to a
low of $14.00 per share and ended that period at $17.5625 per share.
In addition, our results of operations may fluctuate significantly from
quarter to quarter and will depend upon numerous factors, including product
development efforts, actions relating to regulatory and reimbursement matters,
progress and costs related to clinical trials, the extent to which our products
gain market acceptance, and competition. These factors may cause the price of
our stock to fluctuate, perhaps substantially.
Item 2. PROPERTIES
The Company's facilities are located in Norcross, Georgia and consist of two
separate locations totaling approximately 70,000 square feet of leased office
and manufacturing space, including a 1,700 square foot class 100,000 clean room.
Our European operations are housed in a 2,000 square foot leased space in
Brussels, Belgium.
Item 3. LEGAL PROCEEDINGS
None.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable
Item 4A. EXECUTIVE OFFICERS OF THE REGISTRANT
Our executive officers and directors are as follows:
NAME AGE POSITION
---- --- --------
William A. Hawkins........ 46 Chief Executive Officer,
President and Director
Edwin B. Cordell.......... 42 Chief Financial Officer
Michael E. Lussier........ 44 Vice President, European Operations
Cheryl R. Johnson......... 38 Vice President, Investor Relations and
Business Development and Secretary
Adam G. Lowe.............. 38 Vice President, Quality Assurance and
Regulatory Affairs
Daniel G. Hall............ Vice President and General Counsel
Donald J. Webber.......... 38 Vice President, Manufacturing
Douglas B. Schumer, Ph.D.. 50 Vice President, Research and Development
Robert N. Wood, Jr........ 46 Vice President, Sales
Richard diMonda........... 50 Vice President, Marketing
William A. Hawkins. Mr. Hawkins was elected Director in May 1998, joined the
Company as President in June 1998 and became Chief Executive Officer in April
1999. From April 1997 to May 1998, Mr. Hawkins was a Corporate Vice President of
American Home Products Corporation and President of its Sherwood Davis & Geck
division. He is a past board member of the Health Industry Manufacturers
Association (HIMA). Since January 1995, he has been a director of PharmaNetics,
Inc., a Nasdaq-listed company. From October 1995 until April 1997, Mr. Hawkins
was President of Ethicon Endo-Surgery, Inc., a medical device subsidiary of
Johnson & Johnson. From January 1995 to October 1995, Mr. Hawkins served as Vice
President in charge of United States operations of Guidant Corporation and
President of Devices for Vascular Intervention, a medical device company and a
subsidiary of Guidant. Prior to joining Guidant, Mr. Hawkins held several
positions with IVAC Corporation, a medical device company, most recently serving
as President and Chief Executive Officer from 1991 until 1995. Mr. Hawkins holds
a B.S. in Engineering and Biomedical Engineering from Duke University and an
M.B.A. from the University of Virginia.
Edwin B, Cordell, Jr. Mr. Cordell joined the company in May 2000 as Vice
President of Finance and Chief Financial Officer. From November 1994 through
April 2000, Mr. Cordell was Vice President of Finance and Chief Financial
Officer of CryoLife Inc. (NYSE: CRY), a producer of implantable living human
tissues and adhesives for surgical use. From August 1987 to November 1994, Mr.
Cordell served as Controller and Chief Financial Officer of Video Display
Corporation, a publicly held consumer electronics manufacturing and distribution
company. Mr. Cordell, a CPA, received his B.S. in Accounting from the University
of Tennessee.
Michel E. Lussier. Mr. Lussier joined Novoste as Vice President and General
Manager, European Operations in October 1998. Mr. Lussier served as Vice
President and General Manager of European Operations for InControl Inc., a
medical device company, from September 1994 until September 1998, when the
company was acquired by Guidant Corporation. From 1980 to 1994 Mr. Lussier was
employed by Medtronic, Inc., a medical device company, most recently serving as
its European Business Director, Cardiac Pacing. Mr. Lussier is currently Vice
President of the International Association of Prosthesis Manufacturers (IAPM)
and Chairman of its Strategy Committee. Mr. Lussier holds a B.S. in Electrical
Engineering and an M.S. in Biomedical Engineering, both from the University of
Montreal, and he earned an M.B.A. from the European Institute of Business
Administration-INSEAD.
Cheryl R. Johnson. Ms. Johnson joined the Company in July 1992 as Director
of Marketing and Business Development and Secretary, served as Director of
Administration and Business Development of the Company from January 1995 until
July 1996 and has served as Vice President, Investor Relations and Business
Development from July 1996. From August 1989 to June 1992, Ms. Johnson worked
in planning and business development capacities at BOC Health Care, most
recently as its business development manager. Ms. Johnson received an M.B.A.
from the Kellogg School at Northwestern University and a B.S. degree in Chemical
Engineering from the Georgia Institute of Technology.
Adam G. Lowe. Mr. Lowe joined the Company in June 1999 as our Vice
President, Quality Assurance. Effective May 2000, Mr. Lowe also took on the
additional responsibility of Vice President, Regulatory Affairs. From July 1993
to June 1999 Mr. Lowe worked for various divisions of C.R. Bard, Inc., a
diversified medical device manufacturer, having served most recently as the Vice
President, Quality at Bard Access Systems, Mr. Lowe received a B.S. in Materials
Science and Engineering from North Carolina State University and became an ASQ
Certified Quality Engineer in 1992.
Daniel G. Hall. Mr. Hall joined the Company in June 2000 as Vice President
and General Counsel. He served as vice president, secretary and general counsel
of Cordis Corporation beginning in 1981 until the company was acquired by
Johnson & Johnson in 1995. From 1995 to 1999, Mr. Hall managed his own private
law practice. From June 1999, he practiced with Feldman, Gale & Weber, P.A. in
Miami, Florida, serving as managing attorney from December 1999 to June 2000.
Donald J. Webber. Mr. Webber joined the Company in March 1998 as Director of
Manufacturing and has served as our Vice President, Manufacturing since January
2000. From July 1996 through March 1998, Mr. Webber worked for Abiomed, Inc., a
manufacturer of cardiac products, as Director of Operations. From January 1995
to July 1996, Mr. Webber was employed by Cabot Medical Corporation, a medical
device manufacturer, as Plant Manager and from 1988 to 1995 he was employed by
Cordis Corporation, a manufacturer of cardiovascular products. Mr. Webber
received an MBA from Nova Southeastem University and a B.S. degree in Industrial
Engineering from the State University of New York, Binghamton.
Richard diMonda. Mr. diMonda joined the Company in September of 1997 as a
consultant in January 1998 as Senior Director of Strategic Marketing and has
served as our Vice President of Marketing since April of 2000. From March 1987
through August 1997, Mr. diMonda worked for Dornier Medical Systems, Inc., as
Director of Corporate Development. From April 1976 to March 1987, Mr. diMonda
was employed by American Hospital Association as Director, Division of Clinical
Services and Technology. Mr. diMonda received an MBA from Keller Graduate School
of Management, a M.S. degree in Biomedical Engineering from Drexel University,
and a Bachelor of Electrical Engineering from Villanova University.
Douglas B. Schumer, Ph.D. Dr. Schumer joined the company in August 2000 as
Vice President, Research and Development. Prior to joining Novoste, Dr. Schumer
served as Director of Technology Development and Acquisition for Guidant
Corporation. Prior to the formation of Guidant, he previously served as CPI's
Vice President of Research and Development. He joined CPI in 1990. From 1980-
1990 he was employed by Ohaus Corporation, a subsidiary of Mettler/Ciba/Geigy in
various technical management positions, most recently as its Vice President of
Engineering and Research. Dr. Schumer was a member of the technical staff at
Bell Telephone Laboratories from 1977-1980. He graduated from Carnegie Mellon
University with a B.S. in Physics and received a M.S. degree in Measurement and
Control/Instrumentation Science. He received his Ph.D. in Electrical Engineering
from Rensselaer Polytechnic Institute.
Robert N. Wood, Jr. Bob Wood joined the company in June 2000 from Perclose,
a manufacturer of arterial closure devices that was acquired by Abbott
Laboratories in 1999. He served as the Eastern regional sales manager of
Perclose from 1997-2000. From 1987-1997, Mr. Wood was employed by Cordis
Corporation (a Johnson & Johnson Company), where he held various senior sales
management positions, most recently that of national sales manager for Cordis'
Endovascular Systems division. He began his career in the medical device
business as a sales representative for Medrad, Inc. in 1983.
20
PART II
Item 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS
The Company's Common Stock has been traded on the Nasdaq National Market (Nasdaq
symbol: NOVT) since May 1996. The number of record holders of the Company's
Common Stock at February 28, 2001 was 98, excluding beneficial owners of shares
registered in nominee or street name. The Company has not paid any dividends
since its inception, other than the distribution of the Shareholder Rights
described in Item 1: Issuance Of Preferred Stock May Adversely Affect Rights of
Common Shareholders or Discourage a Takeover, and does not intend to pay any
dividends in the foreseeable future.
The range of high and low closing sale prices for the Common Stock is as
follows:
QUARTER ENDED HIGH LOW
---------------------------- -------- ------
Year Ended December 31, 1999
March 31, 1999 $ 30.25 $ 18.875
June 30, 1999 $ 27.875 $ 19.75
September 30, 1999 $ 24.75 $ 16.875
December 31, 1999 $ 17.688 $ 11.00
Year Ended December 31, 2000
March 31, 2000 $ 48.75 $ 17.00
June 30, 2000 $ 61.00 $ 36.2500
September 30, 2000 $60.8125 $ 39.1875
December 31, 2000 $43.4375 $ 22.50
On March 30, 2001 the last reported sale price for the Common Stock was
$17.5625.
Item 6. SELECTED CONSOLIDATED FINANCIAL DATA
The following table sets forth our selected consolidated financial data. The
selected consolidated financial data in the table as of and for the years ended
December 31, 2000, 1999, and 1998 are derived from our consolidated financial
statements which have been audited by Ernst & Young LLP, independent auditors,
as indicated in their report included elsewhere in this Report on Form 10-K. The
selected consolidated financial data as of and for the years ended December 31,
1997 and 1996 are derived from our financial statements which have also been
audited by Ernst & Young LLP and which have not been included in this Report on
Form 10-K. You should read this data in conjunction with the consolidated
financial statements and accompanying notes and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" included elsewhere in
this Report on Form 10-K.
FOR THE YEAR ENDED DECEMBER 31,
-----------------------------------------------------------------
2000 1999 1998 1997 1996
----------- ---------- -------- ---------- --------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
CONSOLIDATED STATEMENT OF OPERATIONS DATA:
Net sales and revenues............................... $ 6,530 $ 1,823 $ 19 $ 29 $ --
Costs and expenses:
Cost of sales...................................... 4,258 1,642 117 -- --
Research and development........................... 17,119 22,889 21,089 12,873 4,647
Sales and Marketing................................ 15,651 6,606 3,074 1,022 581
General and administrative......................... 6,321 3,775 2,528 1,736 1,575
----------- ---------- --------- ---------- ----------
Loss from operations................................. (36,819) (33,089) (26,789) (15,602) (6,803)
Interest income (expense), net....................... 3,745 2,169 2,127 1,389 864
----------- ---------- --------- ---------- ----------
Net loss............................................. $ (33,073) $ (30,920) $(24,662) $ (14,213) $ (5,939)
=========== ========== ========= =========== ==========
Basic and diluted net loss per share(1).............. $ (2.13) $ (2.30) $ (2.34) $ (1.64) $ (0.91)
=========== ========== ========= =========== ==========
Weighted average shares outstanding(1)............... 15,517 13,433 10,536 8,665 6,543
21
AS OF DECEMBER 31,
-----------------------------------------------------------
2000 1999 1998 1997 1996
--------- --------- ---------- ---------- ---------
(IN THOUSANDS)
CONSOLIDATED BALANCE SHEET DATA:
Working capital.......................... $ 53,742 $ 38,090 $ 21,797 $ 46,064 $ 26,849
Total assets............................. 77,073 49,367 29,482 49,796 29,255
Long-term liabilities.................... 401 - - - -
Accumulated deficit...................... (116,275) (83,201) (52,281) (27,619) (13,406)
Total shareholders' equity .............. 67,042 43,065 24,517 47,369 28,434
- --------------
(1) See note 1 to the consolidated financial statements for an explanation of
the method used to compute net loss per share.
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations
FORWARD LOOKING STATEMENTS
The statements contained in this Form 10-K that are not historical
are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
including statements regarding the expectations, beliefs, intentions or
strategies regarding the future. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements reflect
our views as of the date they are made with respect to future events and
financial performance, but are subject to many uncertainties and risks which
could cause our actual results to differ materially from any future results
expressed or implied by such forward-looking statements. Examples of such
uncertainties and risks are discussed under "Item 1--Business" and in this Item
7. Additional risk factors include those that may be set forth in reports filed
by the Company from time to time on Forms 10-K, 10-Q and 8-K. We do not
undertake any obligation to update any forward-looking statements.
OVERVIEW
Novoste commenced operations as a medical device company in May 1992. Since
1994, we have devoted substantially all of our efforts to developing the Beta-
Cath(TM) System. On November 3, 2000, Novoste received U.S. marketing approval
for the Beta-Cath(TM) System from the FDA for use in patients suffering from
"in-stent restenosis", a condition in which coronary stents become clogged with
new tissue growth.
Since our inception through December 31, 2000 we earned minimal revenues and
experienced significant losses in each period. The Company commenced the active
marketing of the Beta-Cath(TM) System in Europe in January 1999. We have
generated only limited revenue and do not have experience in manufacturing,
marketing or selling our products in quantities necessary for achieving
profitability. At December 31, 2000 we had an accumulated deficit of
approximately $116.3 million. We expect to continue to incur significant
operating losses through at least 2001 as we allocate significant resources to
increasing our manufacturing operations, both internally and with outside
vendors, invest significantly in expanding our sales and marketing efforts in
support of United States market development and increase our administrative
activities
22
to support our growth. At the same time we will continue to conduct clinical
trials and research and development projects in order to expand the
opportunities for our technology.
While the Beta-Cath(TM) System has been approved by the FDA for use in patients
suffering from in-stent restenosis, future clinical trials may not demonstrate
the safety and effectiveness of other or different applications or utilizations
of the product. Additionally, the hospitals and catheterization labs that will
be our customers may not obtain necessary approvals for the Beta-Cath(TM) System
from the state, federal or foreign governmental agencies that regulate the
medical use of radiation. Our research and development efforts may not be
successfully completed. Manufacturing of our products may be delayed by
production problems or our vendors may be unable to produce sufficient
quantities to meet our needs. We may not successfully introduce the Beta-
Cath(TM) System or attract any significant level of market acceptance for the
Beta-Cath(TM) System or any other product we develop. We may never achieve
significant revenues from sales of our Beta-Cath(TM) System and we may never
achieve or sustain profitability.
RESULTS OF OPERATIONS
Comparison of Years Ended December 31, 2000 and 1999
The net loss for the year ended December 31, 2000 was $33,073,000, or $2.13 loss
per share, as compared to $30,920,000, or $2.30 loss per share, for the year
earlier. The increase in net loss for the twelve months ended December 31, 2000
was due to increased sales and marketing expenses related to our United States
and European operations compared to the prior year. This was partially offset
by lower clinical trial expenses during the twelve months ended December 31,
2000. The decrease in the loss per share was due to more shares outstanding in
2000 than in 1999.
Net Sales and Revenues. Net sales and revenues were $6,530,000 for the year
ended December 31, 2000 as compared to $1,823,000 for the year ended December
31, 1999. The increase in net sales was primarily due to the increase in number
of active sites, including 21 sites that were opened in the United States
market, and the increase in utilization rates within these sites as compared to
the year earlier period. Within Europe, Germany represented 74% of total
company revenues in the twelve months ended December 31, 2000. Internationally,
with the exception of the Australian and New Zealand distributors, sales are
denominated in Euros. The Euro declined 11% as compared to the year earlier
period. The Company's distributor for the markets of Australia, New Zealand and
China accounted for 20% of net sales in 2000 compared to 14% in 1999.
On November 3, 2000, the FDA granted marketing approval for the Company's Beta-
Cath(TM) System in the United States market, and Novoste began immediately
marketing the product through its direct sales force. The Company earns revenue
from sales of catheters and from sales of license and lease agreements to use
the radiation source trains and transfer devices included in the Beta-Cath(TM)
System. The Company retains ownership of the radiation source trains and
transfer devices and enters into either a one-year lease or license agreement
with its customers. Payments under these arrangements are either due in full at
the inception of the agreement or over the term of the agreement as catheters
are purchased. Revenue recognition begins once an agreement has been executed,
the system has been shipped, and all licensing and other requirements to use the
system have been completed. The Company is dependent upon market acceptance of
the Beta-Cath(TM) System in the United States.
During 1999 and through the second quarter of 2000, all payments under license
agreements were payable at the inception of the agreement. These agreements
were accounted for as sales-type leases and, accordingly, revenue and the
related costs of sales were recognized upon shipment. Beginning in the third
quarter of 2000, after the Company determined the estimated useful life of the
system exceeded one year, license and lease agreements were determined to be
operating leases and, accordingly, revenue has been recorded over the one year
term of the related agreements and costs are recorded over an eighteen month
estimated useful life. During 2000 and 1999, approximately $365,000 and
$713,000, respectively was earned related to the lease of radiation of transfer
devices and is included in net sales and revenue.
The Company has evaluated the impact of Staff Accounting Bulletin (SAB) 101,
Revenue Recognition in Financial Statements, on its revenue recognition policies
and has concluded, based on its current understanding of the SEC's ongoing
interpretation of SAB 101, that the adoption of SAB 101 in 2000 would not
require the Company to change its revenue recognition policies in its Annual
Financial Statements. The Company had previously disclosed and reported in its
Form 10-Q for the quarter ended September 30, 2000, that the adoption of SAB 101
would require a change in its revenue recognition policies. See Note 10.
Cost of Sales. Cost of sales consist primarily of direct labor, allocated
manufacturing overhead, third-party contractor costs, royalties and the
acquisition cost of raw materials and accessories. Our gross margin in 2000 was
$2,272,000, or 35% of net sales, compared to a gross margin of $181,000, 0r
10% of net sales in 1999. The increase in gross margin on both an absolute and
percentage basis is due to the higher sales and production volumes and improved
production yields as the Company transitions out of the start-up phase. The
Company expects gross margins to continue to improve in the future with higher
sales and production volumes.
23
Research and Development Expenses. Research and development expenses decreased
25% to $17,119,000 for the twelve months ended December 31, 2000 from
$22,889,000 for the twelve months ended December 31, 1999. These decreases
were primarily the result of decreased clinical trial expense related to the
completion of patient enrollment in the pivotal trials, the largest expense of
which was the costs of supplying product to clinical sites. Research and
development expenses were favorably impacted by the recent approval of the Beta-
Cath(TM) System. The Company anticipates increasing research and development
expenses in 2001 as it pursues product improvements and line extensions, some of
which may require additional clinical trials.
Sales and Marketing Expenses. Sales and marketing expenses increased 137% to
$15,651,000 for the year ended December 31, 2000 as compared to $6,606,000 for
the previous year. These increases were primarily the result of higher
personnel, trade show, consulting and promotional literature costs associated
with marketing the Company's product on a direct basis in Europe and significant
expenses in recruiting, training and retaining a United States sales force for
the launch of the Beta-Cath(TM) System in the United States. The Company expects
sales and marketing expenses to increase significantly in the future as direct
distribution is expanded in Europe and the United States.
General and Administrative Expenses. General and administrative expenses
increased 67% to $6,321,000 for the year ended December 31, 2000 from $3,775,000
for the year ended December 31, 1999. The increase for this twelve month period
was primarily the result of additional management personnel and higher salaries
and the increase in infrastructure (accounting, information systems, human
resources and benefits) to support a commercial company. The Company expects
general and administrative expenses to continue to increase in the future in
support of a higher level of operations.
Interest Income. Net interest income increased 72% to $3,745,000 for the twelve
months ended December 31, 2000 from $2,169,000 for the same period a year
earlier. The increase in interest income for the quarter and the year-to-date
was primarily due to the increase in average cash equivalent and short-term
investment balances arising from the private placement equity offering in March
and April 2000, as well as an increase in cash on hand due to a large number of
stock option exercises at the end of June, 2000.
Comparison of Years Ended December 31, 1999 and 1998
The net loss for the year ended December 31, 1999 was $30,920,000, or
($2.30) per share, as compared to $24,662,000, or ($2.34) per share, for the
year earlier. The increase in net loss for the year ended December 31, 1999 was
due primarily to increased spending related to the Company's clinical trials as
well as sales and marketing expenses related to the Company's direct sales
operation in Europe.
Net Sales and Revenues. Net sales and revenues were $1,823,000 for the year
ended December 31, 1999 as compared to $19,000 for the year ended December 31,
1998. The Company recorded its first sale of the Beta-Cath(TM) System in
December 1998 and began actively marketing the device during the second quarter
of 1999. Net sales and revenues includes sales of the Beta-Cath(TM) catheter and
installation fees for the Beta-Cath(TM) transfer device. The Company's
distributor for the markets of Australia, New Zealand and China accounted for
14% of net sales in 1999.
Cost of Sales. Cost of sales consist primarily of direct labor, allocated
manufacturing overhead, third-party contractor costs, royalties and the
acquisition cost of raw materials and accessories. Our gross margin in 1999 was
$181,000, or 10% of net sales, compared to a negative gross margin of ($98,000)
in 1998. The increase in gross margin on both an absolute and percentage basis
is due to the higher sales and production volumes and improved production yields
as the Company transitions out of the start-up phase. The Company expects gross
margins to continue to improve in the future with higher sales and production
volumes.
Research and Development Expenses. Research and development expenses
increased 9% to $22,889,000 for the year ended December 31, 1999 from
$21,089,000 for the year ended December 31, 1998. These increases were primarily
a result of (a) costs of patient enrollment and follow-up in three pivotal
clinical trials: the Beta-Cath(TM) System Trial, the START Trial and the START
40 Trial, as well as a market registry trial in Europe; (b) the cost of
supplying the Beta-Cath(TM) System to all the clinical sites; (c) legal and
filing costs associated with domestic and foreign patent applications; and (d)
costs related to the ongoing development of the Beta-Cath(TM) System; including
a smaller radiation source and catheter.
Sales and Marketing Expenses. Sales and marketing expenses increased 215% to
$6,606,000 for the year ended December 31, 1999 from $3,074,000 for the year
ended December 31, 1998. These increases were primarily the result of higher
personnel, trade show, consulting and promotional literature costs associated
with launching the Company's product and setting up a direct sales
24
operation in Europe. The Company expects sales and marketing expenses to
increase significantly in the future as distribution is expanded in Europe, and
if and when the Beta-Cath(TM) System is approved by the FDA and launched
commercially in the U.S.
General and Administrative Expenses. General and administrative expenses
increased 49% to $3,775,000 for the year ended December 31, 1999 from $2,528,000
for the year ended December 31, 1998. These increases were primarily the result
of additional management personnel, higher salaries and costs associated with
the installation and implementation of the Company's new software system. The
Company expects general and administrative expenses to increase in the future in
support of a higher level of operations.
Interest Income. Interest income increased 2% to $2,169,000 for the year
ended December 31, 1999 from $2,127,000 for the year ended December 31, 1998.
The increase in net interest income was primarily due to larger average cash
equivalents and short-term investment balances after the Company's secondary
public offering in March 1999.
LIQUIDITY AND CAPITAL RESOURCES
During the years ended December 31, 2000, 1999 and 1998, the Company used cash
to fund operations of $30.2 million, $30.8 million, and $21.4 million,
respectively. At December 31, 2000 the Company had commitments to purchase $7.4
million in inventory components of the Beta-Cath(TM) System over the next year.
In addition, on October 14, 1999 the Company signed a development and
manufacturing supply agreement with AEA Technologies QSA GmbH for a second
source of radioisotope supply and for the development of a smaller diameter
source. This agreement provides for the construction of a production line over
the period October 1, 1999 to August 2001. The cost of this production line is
estimated at $4.0 million and is being paid by the Company as construction
progresses. Through December 31, 2000, the Company has paid $2,377,000 towards
this commitment. Because of the development, manufacturing scale-up and
commercialization of the Beta-Cath(TM) System, Novoste's future cash needs for
operating and investing activities are anticipated to be higher than historical
levels subject to the factors discussed below.
Significant proportions of key components and processes relating to the
Company's products are purchased from single sources due to technology,
availability, price, quality, and other considerations. Key components and
processes currently obtained from single sources include isotopes, protective
tubing for catheters, proprietary connectors, and certain plastics used in the
design and manufacture of the transfer device. In the event a supply of a key
single-sourced material or component was delayed or curtailed, the Company's
ability to produce the related product in a timely manner could be adversely
affected. The Company attempts to mitigate these risks by working closely with
key suppliers regarding the Company's product needs and the maintenance of
strategic inventory levels.
The Company has entered into a license agreement with a physician pursuant to
which he is entitled to receive a royalty on the net sales of the Beta-Cath(TM)
System (excluding consideration paid for the radioactive isotope), subject to a
maximum payment of $5,000,000. Royalty fees to the physician aggregated $63,200
and $11,250 in 2000 and 1999 and have been expensed in Cost of Sales. No royalty
fees were paid in 1998 under this license agreement.
On January 30, 1996, the Company entered into a license agreement whereby Emory
University assigned its claim to certain technology to the Company for royalties
based on net sales (as defined in the agreement) of products derived from such
technology, subject to certain minimum royalties. The royalty agreement term is
consistent with the life of the related patent and applies to assignments of the
patent technology to a third party. Royalty fees to Emory University aggregated
$146,050 and $36,330 in 2000 and 1999 and have been expensed in Cost of Sales.
No royalty fees were paid in 1998 under this license agreement.
On March 19, 1999 the Company completed a follow-on public offering of 2,400,000
newly issued shares of its common stock at a public offering price of $20 per
share. On March 24, 1999 the Company issued an additional 160,000 shares of
common stock pursuant to the exercise of the underwriters' over-allotment
option. Net proceeds to the Company after the exercise of the underwriters'
over-allotment option and all related expenses totaled $47.4 million.
25
On April 7, 2000 the Company completed a private placement offering, in which we
sold 1,463,500 shares of our common stock at $35.00 per share. The placement
raised net proceeds of approximately $49 million, of which $5 million was
received during the second quarter. After the offering, we had 15.85 million
shares of common stock outstanding. The Company also received approximately
$7.1 million during the year from the exercise of stock options.
The Company's principal source of liquidity at December 31, 2000 consisted of
cash, cash equivalents and short-term investments of $57.2 million. The Company
did not have any credit lines available or outstanding borrowings at
December 31, 2000.
The Company anticipates that its operating losses will continue through at least
2001 as it expends substantial resources to expand sales and marketing
activities. We believe that our existing capital resources will be sufficient to
fund the Company through the second quarter of 2002, but those resources may
prove insufficient. The Company's future liquidity and capital requirements will
depend upon numerous factors, including, among others: market acceptance and
demand for its products; the resources required to maintain a direct sales force
in the United States and in the larger markets of Europe, develop distributors
internationally, and to expand manufacturing capacity; the resources the Company
devotes to the development, manufacture and marketing of its products; the
receipt of and the time required to obtain additional regulatory clearances and
approvals; the resources required to gain such approvals; and the progress of
the Company's clinical research and product development programs. Novoste may
in the future seek to raise additional funds through bank facilities, debt or
equity offerings or other sources of capital. Additional financing, if
required, may not be available on satisfactory terms, or at all.
Item 7a. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
INTEREST RATE RISK
The Company's cash equivalents and short-term investments are subject to market
risk, primarily interest-rate and credit risk. The Company's investments are
managed by outside professional managers within investment guidelines set by the
Company. Such guidelines include security type, credit quality and maturity and
are intended to limit market risk by restricting the Company's investments to
high credit quality securities with relatively short-term maturities.
At December 31, 2000, the Company had $21.7 million in cash equivalents with a
weighted average interest rate of 6.32% and $30.7 million in available for sale
investments with a weighted average interest rate of 6.67%. At December 31, 1999
the Company had $6.8 million in cash equivalents with a weighted average
interest rate of 5.92% and $34.3 million in available for sale investments with
a weighted average interest rate of 5.55%. All investments mature, by policy, in
one year or less.
FOREIGN CURRENCY RISK
International revenues from the Company's foreign direct sales and distributor
sales comprised 72% of total revenues for the year ended December 31, 2000 and
100% for the year ended December 31, 1999. With the exception of the Australian,
Chinese and New Zealand distributor, which sales are denominated in U.S.
dollars, sales are denominated in Euros. The Company experienced an immaterial
amount of transaction gains and losses for the year ended December 31, 2000. The
Company is also exposed to foreign exchange rate fluctuations as the financial
results of its Dutch, Belgian, German and French subsidiaries are translated
into U.S. dollars in consolidation. As exchange rates vary, these results
26
when translated, may vary from expectations and adversely impact overall
expected profitability. The net effect of foreign exchange rate fluctuations on
the Company during the year ended December 31, 2000 was not material.
Item 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements, with the report of the independent
auditors, listed in Item 14, are included in this Annual Report on Form 10-K.
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING FINANCIAL
DISCLOSURE
Not applicable.
27
PART III
Incorporated by reference.
This information required by Part III of this Form 10-K is omitted from this
Report in that the Registrant will file a definitive proxy statement pursuant to
Regulation 14(a) for its 2001 Annual Meeting of Stockholders (the "Proxy
Statement") not later than 120 days after the end of the fiscal year covered by
this Report, and certain information included therein is incorporated herein by
reference.
Item 10. Directors and Executive Officers of the Registrant
The information on directors required by Items 401 and 405 of Regulation S-K is
incorporated herein by reference to the Company's definitive Proxy Statement
("Proxy Statement"), which will be filed with the Securities and Exchange
Commission ("SEC") within 120 days after December 31, 2000.
Information concerning the Company's executive officers required by Item 401(b)
of Regulation S-K appears in Part I of this Annual Report on Form 10-K.
Item 11. Executive Compensation
The information required by Item 402 of Regulation S-K is incorporated herein by
reference to the Company's Proxy Statement, which will be filed with the SEC
within 120 days after December 31, 2000, except that the Report of the
Compensation Committee and the Stock Performance Graph contained in the Proxy
Statement are specifically excluded from incorporation by reference
herein.
Item 12. Security Ownership of Certain Beneficial Owners and Management
The information required by Item 403 of Regulation S-K is incorporated herein by
reference to the Company's Proxy Statement, which will be filed with the SEC
within 120 days after December 31, 2000.
Item 13. Certain Relationships and Related Transactions
The information required by Item 404 of Regulation S-K is incorporated herein by
reference to the Company's Proxy Statement, which will be filed with the SEC
within 120 days after December 31, 2000.
28
PART IV
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) 1. Index to Financial Statements.
The following consolidated financial statements of Novoste Corporation are
included herein:
Page Number
Report of Independent Auditors [F-1]
Consolidated Balance Sheets as of December 31, 2000 and 1999 [F-2]
Consolidated Statements of Operations for the years ended
December 31, 2000, 1999 and 1998 [F-3]
Consolidated Statements of Shareholders' Equity for the years ended
December 31, 2000, 1999 and 1998 [F-4]
Consolidated Statements of Cash Flows for the years ended
December 31, 2000, 1999 and 1998 [F-5]
Notes to Consolidated Financial Statements [F-6]
2. Financial Statement Schedules.
Information required by consolidated financial statement schedules for which
provision is made in the applicable accounting regulation of the Securities and
Exchange Commission is included in the Notes to Consolidated Financial
Statements; thereby eliminating the needs for these schedules.
3. Exhibits.
The exhibits listed in the accompanying Index to Exhibits immediately following
the financial statement schedules are filed with this report.
(b)
Reports on Form 8-K.
The following reports were filed on Form 8-K by the Registrant during the fiscal
quarter ended December 31, 2000.
1. The Company filed a Form 8-K on October 17, 2000 to disclose under "Item 5 -
Other Events" a press release announcing that it had received a letter from the
U.S. Food and Drug Administration stating that its Beta-Cath(TM) System is
approvable. The Company also announced the dates when results of various
clinical trials would be announced at scientific meetings. In the same Form 8-K
under Item 5 - Other Events, the Company disclosed that it had issued a press
release announcing the third quarter 2000 financial results.
2. The Company filed a Form 8-K on October 19, 2000 to disclose under "Item 5
- - Other Events" a press release announcing that interim results of the
Registrant's START 40 Trial were presented at the Transcatheter Cardiovascular
Therapeutics (TCT) conference in Washington, D.C.
Exhibits - The response to this portion of Item 14 is submitted as a separate
section of this report commencing on page __ of this report.
29
REPORT OF INDEPENDENT AUDITORS
The Board of Directors and Shareholders
Novoste Corporation
We have audited the accompanying consolidated balance sheets of Novoste
Corporation (the "Company") as of December 31, 2000 and 1999, and the related
consolidated statements of operations, shareholders' equity, and cash flows for
each of the three years in the period ended December 31, 2000. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of the Company at
December 31, 2000 and 1999, and the consolidated results of their operations and
their cash flows for each of the three years in the period ended December 31,
2000, in conformity with accounting principles generally accepted in the United
States.
Ernst & Young LLP
Atlanta, Georgia
January 29, 2001
30
NOVOSTE CORPORATION
CONSOLIDATED BALANCE SHEETS
DECEMBER 31,
---------------------------------
2000 1999
---------------------------------
ASSETS
Current assets:
Cash and cash equivalents.................................. $ 26,512,398 $ 7,091,025
Short-term investments..................................... 30,655,436 34,332,667
Accounts receivable, net of allowance of $311,310
and $0, respectively (Note 1)............................. 4,469,781 968,804
Inventories................................................ 1,251,687 2,513,981
Prepaid expenses and other current assets.................. 482,383 216,742
------------- ---------------
Total current assets.................................... 63,371,685 43,123,219
------------- ---------------
Property and equipment, net.................................. 7,277,734 3,509,203
Radiation and transfer devices, net.......................... 5,480,948 -
Other assets................................................. 942,427 734,980
------------- ---------------
$ 77,072,794 $ 49,367,402
============= ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable........................................... $ 3,425,250 $ 1,112,678
Accrued expenses........................................... 5,415,277 5,189,880
Deferred revenue........................................... 580,817 -
Capital lease obligations.................................. 208,805 -
------------- ---------------
Total current liabilities.................................... 9,630,149 6,302,558
------------- ---------------
Long-term liabilities:
------------- ---------------
Capital lease obligations.................................. 400,526 -
------------- ---------------
Shareholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares
authorized, no shares issued and outstanding.............. - -
Common stock, $.01 par value, 25,000,000 shares
authorized; 16,094,635 and 14,201,632 shares issued,
respectively.............................................. 160,946 142,016
Additional paid-in capital.................................. 184,511,610 128,182,542
Accumulated other comprehensive (loss) income............... (93,690) 57,722
Accumulated deficit......................................... (116,274,687) (83,201,214)
------------- ---------------
68,304,179 45,181,066
Less treasury stock, 5,780 shares of common stock at........ (23,840) (23,840)
cost
Unearned compensation....................................... (1,238,220) (2,092,382)
------------- ---------------
Total shareholders' equity.............................. 67,042,119 43,064,844
------------- ---------------
$ 77,072,794 $ 49,367,402
============= ===============
See accompanying notes
31
NOVOSTE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
YEAR ENDED DECEMBER 31,
--------------------------------------------------
2000 1999 1998
--------------------------------------------------
Net sales and revenue........... $ 6,529,581 $ 1,823,394 $ 18,775
Cost of sales................... 4,257,602 1,642,395 116,633
--------------------------------------------------
Gross margin.................... 2,271,979 180,999 (97,858)
Operating expenses:
Research and development....... 17,118,976 22,889,182 21,088,740
Sales and marketing............ 15,650,756 6,606,337 3,074,245
General and administrative..... 6,321,186 3,775,154 2,527,917
--------------------------------------------------
Total operating expenses........ 39,090,918 33,270,673 26,690,902
--------------------------------------------------
Loss from operations............ (36,818,939) (33,089,674) (26,788,760)
--------------------------------------------------
Interest income, net............ 3,745,466 2,169,462 2,126,867
--------------------------------------------------
Net loss........................ $ (33,073,473) $ (30,920,212) $ (24,661,893)
==================================================
Net loss per share-basic and
diluted......................... $ (2.13) $ (2.30) $ (2.34)
Weighted average shares
outstanding..................... 15,517,272 13,433,226 10,536,034
See accompanying notes.
32
NOVOSTE CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2000, 1999 AND 1998
Accumulated
Common Stock Additional Other
--------------------- Paid-In Comprehensive Accumulated Treasury Unearned
Shares Amount Capital Income Deficit Stock Compensation TOTAL
-------------------------------------------------------------------------------------------------------
Balance at January 1, 1998 10,332,042 $ 103,320 $74,908,631 $ - $(27,619,109) $(23,840) $ - $ 47,369,002
Issuance of stock for
consulting services,
10,000
shares at $29.625 per
share, 3,000 shares at
$22.0625 per share 13,000 130 632,308 - - - - 632,438
Issuance of stock for
deferred compensation to
an officer, at $25.75 per
share 14,000 140 360,360 - - - (360,500) -
Issuance of stock for
compensation to an officer,
at $25.75 per share 6,000 60 154,440 - - - - 154,500
Amortization of unearned
compensation - - - - - - 52,573 52,573
Exercise of stock options
at $0.25 to $16.00 per share 339,775 3,398 967,075 - - - - 970,473
Net loss - - - - (24,661,893) - - (24,661,893)
------------------------------------------------------------------------------------------------------
Balance at December 31, 1998 10,704,817 107,048 77,022,814 (52,281,002) (23,840) (307,927) 24,517,093
Issuance of stock in
secondary offering at $20
per share, net of issuance
costs of $3,776,228 2,560,000 25,600 47,398,172 - - - - 47,423,772
Issuance of restricted Stock
for compensation to
officers, 10,000 shares
at $23.56, 25,000 shares
at $20.75 35,000 350 754,025 - - - (754,375) -
Deferred compensation
relating to issuance of
certain stock options - - 1,792,500 - - - (1,792,500) -
Deferred consulting
charges on stock option
grants - - 234,597 - - - - 234,597
Amortization of unearned
compensation and
deferred consulting - - 112,500 - - - 762,420 874,920
Exercise of stock options at
$0.25 to $17.25 per share 901,815 9,018 867,934 - - - - 876,952
Comprehensive income (loss):
Translation adjustment - - - 57,722 - - - 57,722
Net loss - - - - (30,920,212) - - (30,920,212)
-----------
Total comprehensive loss - - - - - - - (30,862,490)
------------------------------------------------------------------------------------------------------
Balance at December 31, 1999 14,201,632 142,016 128,182,542 57,722 (83,201,214) (23,840) (2,092,382) 43,064,844
33
Issuance of Stock in private
placement, 1,463,500 shares
at $35 per share, net of
issuance cost of $2,525,275 1,463,500 14,635 48,682,590 - - - - 48,697,225
Issuance of restricted stock for
compensation to officer and
employees, 1500 shares at
$41 per share, 1,950 shares
at $22.50 per share 3,450 35 105,340 - - - (105,375) -
Cancellation of unvested
equity awards issued to
officer (7,500) (75) (249,300) - - - 249,375 -
Other equity transactions - - 114,880 - - - - 114,880
Amortization of unearned
compensation - - - - - - 710,162 710,162
Deferred consulting charges
on stock option grants - - 328,876 - - - - 328,876
Exercise of stock options at
$1.00 to $29.63 426,544 4,265 7,141,874 - - - - 7,146,139
Issuance of stock under
employee stock purchase
plan, 3,219 shares at $36.125
and 3,790 shares at $23.375 7,009 70 204,808 - - - - 204,878
Comprehensive loss:
Translation Adjustment - - - (151,412) - - - (151,412)
Net loss (33,073,473) (33,073,473)
------------
Comprehensive loss (33,224,885)
------------------------------------------------------------------------------------------------
16,094,635 $160,946 $184,511,610 $(93,690) $(116,274,687) $(23,840) $(1,238,220) $ 67,042,119
========== ======== ============ ======== ============= ======== =========== ============
See accompanying notes.
34
NOVOSTE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31,
----------------------------------------------------
2000 1999 1998
----------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss...................................................... $ (33,073,473) $ (30,920,212) $ (24,661,893)
Adjustments to reconcile net loss to net cash used by
operating activities:
Depreciation and amortization................................ 1,456,892 929,769 671,286
Amortization of radiation and transfer devices............... 131,815
Issuance of stock for services or compensation............... 328,877 347,097 786,938
Amortization of deferred compensation........................ 710,162 762,420 250,274
Provision for doubtful accounts.............................. 311,310 - -
Change in assets and liabilities:
Accounts receivable.......................................... (3,812,287) (960,029) (8,775)
Inventory.................................................... 1,262,294 (1,976,630) (537,351)
Prepaid expenses and other current assets................... (265,640) (48,600) (80,043)
Accounts payable............................................. 2,312,572 53,087 535,913
Accrued expenses and taxes withheld.......................... 225,397 1,284,332 2,002,272
Deferred revenue............................................. 580,817 - -
Other........................................................ (374,298) (298,366) (360,254)
---------------------------------------------------
Net cash used by operations................................... (30,205,562) (30,827,132) (21,401,633)
CASH FLOWS FROM INVESTING ACTIVITIES
Maturities (purchase) of short-term investments, net.......... 3,677,231 (10,637,216) (11,286,666)
Purchase of property and equipment............................ (4,548,405) (2,097,868) (1,923,590)
Purchase of radiation and transfer devices.................... (5,612,763)
---------------------------------------------------
Net cash used by investing activities......................... (6,483,937) (12,735,084) (13,210,256)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock........................ 56,163,120 48,300,724 970,473
Payments on capital lease obligations......................... (52,248) - -
---------------------------------------------------
Net cash provided by financing activities..................... 56,110,872 48,300,724 970,473
Net increase (decrease) in cash and cash equivalents.......... 19,421,373 4,738,508 (33,641,416)
Cash and cash equivalents at beginning of period.............. 7,091,025 2,352,517 35,993,933
---------------------------------------------------
Cash and cash equivalents at end of period.................... $ 26,512,398 $ 7,091,025 $ 2,352,517
===================================================
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest on capital lease obligations.......... $ 17,004 $ - $ -
Noncash investing and financing activities:
Assets acquired under capital leases 661,000 - -
See accompanying notes.
35
NOVOSTE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND BASIS OF PRESENTATION
Novoste Corporation (the "Company") was incorporated on January 8, 1987 and
remained dormant until May 22, 1992 (date of inception) at which time it was
capitalized. The Company is a medical device company that is engaged in
commercializing the Beta-Cath(TM) System, an intraluminal beta radiation
catheter delivery system designed to reduce restenosis subsequent to
percutaneous transluminal coronary angioplasty. In the course of its development
activities the Company has sustained operating losses and expects losses to
continue for at least the next year.
During years prior to 1998 the Company was in the development stage. In 1998 the
Company received CE mark approval to sell the Beta-Cath(TM) System in Europe and
recorded its first sale of commercial product in December 1998. In 2000, the
Company received FDA approval to sell the Beta-Cath(TM) System in the United
States. To achieve profitable operations, the Company must successfully obtain
additional regulatory approvals and achieve market acceptance. The Company plans
to finance the Company with revenues from product sales. The Company's ability
to continue its operations is dependent upon successful market acceptance and
achieving profitable operations.
The consolidated financial statements include the accounts of Novoste
Corporation and its wholly-owned subsidiaries incorporated in The Netherlands,
Belgium, Germany and France. Significant intercompany accounts and transactions
have been eliminated.
ACCOUNTS RECEIVABLE
Accounts receivable at December 31, 2000 and 1999 includes receivables due from
product sales and amounts due under lease arrangements relating to radiation and
transfer devices (see Radiation and Transfer Devices). The carrying amounts
reported in the consolidated balance sheets for accounts receivable approximate
their fair value.
The Company's distributor for the markets of Australia, New Zealand and China
accounted for 20% of net sales in 2000 and 14% in 1999. The Company performs
periodic credit evaluations of its customer's financial condition and generally
does not require collateral. Management records estimates of expected credit
losses and returns of product sold. Bad debt expense for the year ended December
31, 2000 amounted to $311,000. There were no uncollectible accounts written off
during 2000. No bad debt expense was recognized for the years
ended December 31, 1999 and 1998.
BASIC AND DILUTED LOSS PER SHARE
The basic and diluted loss per share is computed based on the weighted average
number of common shares outstanding. Common equivalent shares of 2,483,157 are
not included in the per share calculations where the effect of their inclusion
would be antidilutive.
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
The Company maintains cash equivalents and investments in several large
well-capitalized financial institutions. The Company's investment policy does
not allow investment in any debt securities rated less than "investment-grade"
by national ratings services. Cash equivalents are comprised of certain highly
liquid investments with maturities of less than three months. In addition to
cash equivalents, the Company has investments in commercial paper and
certificates of deposit that are classified as short-term (mature in more than
90 days but less than one year).
Management determines the appropriate classification of debt securities at the
time of purchase and reevaluates such designation as of each balance sheet date.
These investments are accounted for in accordance with Statement of Financial
Accounting Standards ("SFAS") No. 115, Accounting for Certain Investments in
Debt and Equity Securities ("SFAS 115"). The Company has classified all short
and long-term investments as available for sale. Available for sale securities
are carried at fair value, with the unrealized gains
36
and losses reported in a separate component of stockholder's equity if
significant. Realized gains and losses are included in investment income and are
determined on a specific identification basis (Note 5).
CONCENTRATIONS OF FINANCE RISK
The Company's cash equivalents and short-term investments are subject to market
risk, primarily interest-rate and credit risk. The Company's investments are
managed by outside professional managers within investment guidelines set by the
Company. Such guidelines include security type, credit quality and maturity and
are intended to limit market risk by restricting the Company's investments to
high credit quality securities with relatively short-term maturities.
FOREIGN CURRENCY RISK
International revenues from the Company's foreign direct sales and distributor
sales comprised 74% and 100% of total revenues for the year ended December 31,
2000 and December 31, 1999, respectively. With the exception of the Australian,
Chinese and New Zealand distributor, sales are denominated in Euros. The Company
experienced an immaterial amount of transaction gains and losses in 2000. The
Company is also exposed to foreign exchange rate fluctuations as the financial
results of its Dutch, Belgian, German and French subsidiaries are translated
into U.S. dollars in consolidation. As exchange rates vary, these results, when
translated, may vary from expectations and adversely impact overall expected
profitability. The net effect of foreign exchange rate fluctuations on the
Company during 2000 was not material.
INVENTORIES
Inventories are stated at the lower of cost or market and are comprised of the
following:
December 31, 2000 December 31, 1999
-------------------------------------------------
Raw materials. $ 777,819 $ 380,589
Work in process 218,958 21,518
Finished goods 254,910 2,111,874
-------------------------------------------------
Total $ 1,251,687 $ 2,513,981
=================================================
PROPERTY AND EQUIPMENT
Property and equipment are stated at cost. Depreciation is computed using the
straight-line method over the estimated useful lives of the assets ranging from
three to seven years. Leasehold improvements are amortized over the remaining
term of the underlying lease using the straight-line method. Repairs and
maintenance are expensed as incurred.
Property and equipment is comprised of the following:
December 31, 2000 December 31, 1999
-------------------------------------------
Furniture and fixtures $ 1,217,807 $ 820,285
Office equipment 3,632,468 2,167,823
Laboratory equipment 570,719 300,555
Leasehold improvements 1,585,553 1,174,191
Production equipment 4,097,877 1,431,585
------------------------------------------
11,104,424 5,894,439
Less: Accumulated depreciation and
amortization (3,826,690) (2,385,236)
------------------------------------------
$ 7,277,734 $ 3,509,203
==========================================
37
LONG-LIVED ASSETS
In accordance with Statement of Financial Accounting Standards No. 121,
Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
be Disposed Of ("SFAS 121"), long-lived assets are reviewed for impairment
whenever events indicate that their carrying amount may not be recoverable. In
such reviews, estimated undiscounted future cash flows associated with these
assets are compared with their carrying value to determine if a write-down to
fair value (normally measured by discounting estimated future cash flows) is
required.
RADIATION AND TRANSFER DEVICES
The Company retains ownership of the radiation source trains (RSTs) and transfer
devices (TDs). During 1999, the Company was the lessor of RSTs and TDs under
annual sales-type lease agreements expiring through December 2000. At December
31, 1999, future minimum lease payments receivable under these sales-type leases
approximated $159,000 and are recorded in accounts receivable.
During the second quarter of 2000, the Company determined that based upon
experience, testing and discussions with the FDA the estimated useful life of
RSTs and TDs would exceed one year. Accordingly, the Company has reclassified
these assets from inventory to a long-term asset named, radiation and transfer
devices. Depreciation of the costs of these assets will be over their estimated
useful lives (currently estimated at 18 months) using the straight-line method
and will begin once the Beta-Cath(TM) System is placed into service. Concurrent
with the change in estimated life, the RST and TD annual agreements to license
the use of the radiation and transfer devices are classified by the Company as
operating leases. At December 31, 2000, equipment with a cost of approximately
$1,020,000 net of accumulated depreciation of approximately $132,000 were under
operating leases. Approximately $4,592,000 of radiation and transfer devices
were available for lease at December 31, 2000. At December 31, 2000, future
minimum lease payments receivable under these operating leases approximated
$557,000 and are recorded in accounts receivable.
Radiation and transfer devices are stated at cost and are comprised of the
following:
December 31, 2000
-----------------
Radiation and transfer devices $ 5,612,763
Less: Accumulated depreciation 131,815
-----------------
$ 5,480,948
=================
REVENUE RECOGNITION
The Company earns revenue from sales of catheters and from license and lease
agreements to use the radiation source trains and transfer devices included in
the Beta-Cath(TM) System.
The Company recognizes revenue from sales of catheters to distributors at the
time of shipment. Revenue from sales of catheters directly to hospitals are
recognized upon shipment and when the hospital has leased a Beta-Cath(TM) System
and completed all licensing and other requirements to use the system.
The Company retains ownership of the radiation source trains and transfer
devices and enters into either a one-year lease or license agreement with its
customers. Payments under these arrangements are either due in full at the
inception of the agreement or over the term of the agreement as catheters are
purchased. Revenue recognition begins once an agreement has been executed, the
system has been shipped, and all licensing and other requirements to use the
system have been completed.
During 1999 and through the second quarter of 2000, all payments under license
agreements were payable at the inception of the agreement. These agreements were
accounted for as sales-type leases and, accordingly, revenue and the related
costs of sales were recognized upon shipment. Beginning in the third quarter of
2000, after the Company determined the estimated useful life of the system
exceeded one year, license and lease agreements were determined to be operating
leases and, accordingly, revenue has been recorded over the one year term of the
related agreements and costs are recorded over an eighteen month estimated
useful life. During 2000 and 1999, approximately $365,000 and $713,000,
respectively was earned related to the lease of radiation transfer devices and
is included in net sales and revenue.
The Company has evaluated the impact of Staff Accounting Bulletin (SAB) 101,
Revenue Recognition in Financial Statements, on its revenue recognition policies
and has concluded, based on its current understanding of the SEC's ongoing
interpretation of SAB 101, that the adoption of SAB 101 in 2000 would not
require the Company to change its revenue recognition policies in its Annual
Financial Statements. The Company had previously disclosed and reported in its
Form 10-Q for the quarter ended September 30, 2000, that the adoption of SAB 101
would require a change in its revenue recognition policies. See Note 10.
38
RESEARCH AND DEVELOPMENT AND PATENT COSTS
All research and development costs are charged to operations as incurred. Legal
fees and other direct costs incurred in obtaining and protecting patents are
expensed as incurred.
SHIPPING COSTS
All shipping costs incurred by the Company are classified as Cost of Sales.
STOCK BASED COMPENSATION
SFAS No. 123, Accounting for Stock-Based Compensation ("SFAS 123") sets forth
accounting and reporting standards for stock-based employee compensation plans
(Note 7). As permitted by SFAS 123, the Company accounts for stock options
grants in accordance with Accounting Principles Board Opinion No. 25, Accounting
for Stock Issued to Employees ("APB 25") and related interpretations. Under APB
25 no compensation expense is recognized for stock option grants to employees
for which the terms are fixed. The Company grants stock options generally for a
fixed number of shares to employees, directors, consultants and independent
contractors with an exercise price equal to the fair market value of the shares
at the date of grant. Compensation expense is recognized for increases in the
estimated fair value of common stock for any stock options with variable terms.
The Company accounts for equity instruments issued to nonemployees in accordance
with the provisions of SFAS 123 and Emerging Issues Task Force (EITF) Issue No.
96-18, Accounting for Equity Instruments that Are Issued to Other than Employees
for Acquiring, or in Conjunction with Selling, Goods or Services.
Any compensation expense related to grants that do not vest immediately is
amortized over the vesting period of the stock options using the straight-line
method as that methodology most closely approximates the way in which the option
holder earns those options.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes.
Actual results could differ from those estimates.
NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133,
Accounting for Derivative Investments and Hedging Activities ("SFAS 133"). SFAS
133 established a new model for accounting for derivatives and hedging
activities and supersedes several existing standards. SFAS 133, as amended by
SFAS 137 and SFAS 138, is effective for all fiscal quarters of fiscal years
beginning after June 15, 2000. The Company does not expect that the adoption of
SFAS 133 will have a material impact on its financial statements.
RECLASSIFICATIONS
Certain amounts have been reclassified in prior year statements to conform to
current year presentation.
2. CONSULTING AGREEMENTS
The Company has agreements with certain physicians, various consultants and
others with terms ranging from one to five years. Substantially all of these
agreements provide for stock or stock option grants on the agreement dates.
Shares issued under these agreements are generally valued at fair value on the
date of grant and include certain registration rights. Stock option grants under
these agreements are measured in accordance with EITF 96-18, Accounting for
Equity Instruments That Are Issued for Sales of Goods and Services to Other Than
Employees. During 2000, 1999, and 1998 approximately $399,000, $374,000, and
$198,000, respectively, was charged to operations as amortization of deferred
compensation under these agreements in accordance with their vesting terms. As
of December 31, 2000, all stock and stock option grants issued under these
consulting agreements were vested.
39
3. COMMITMENTS AND CONCENTRATIONS OF SUPPLIERS
The Company is committed under operating leases for its facility and various
office equipment. Rent expense was approximately $707,000, $607,000 and $199,000
for 2000, 1999, and 1998, respectively. The total future minimum rental payments
are as follows:
2001....................... $ 1,017,503
2002....................... 883,564
2003....................... 758,387
2004....................... 17,000
2005....................... --
------------------
$ 2,676,454
==================
The Company has entered into a license agreement with a physician pursuant to
which he is entitled to receive a royalty on the net sales of the Beta-Cath(TM)
System (excluding consideration paid for the radioactive isotope), subject to a
maximum payment of $5,000,000. Royalty fees to the physician aggregated $63,200
and $11,250 in 2000 and 1999 and have been expensed in Cost of Sales. No royalty
fees were paid in 1998 under this license agreement.
On January 30, 1996, the Company entered into a license agreement whereby Emory
University assigned its claim to certain technology to the Company for royalties
based on net sales (as defined in the agreement) of products derived from such
technology, subject to certain minimum royalties. The royalty agreement term is
consistent with the life of the related patent and applies to assignments of the
patent technology to a third party. Royalty fees to Emory University aggregated
$146,050 and $36,330 in 2000 and 1999 and have been expensed in Cost of Sales.
No royalty fees were paid in 1998 under this license agreement.
During 2000, 1999, and 1998, the Company obtained all of its requirements of
radiation source materials (totaling $1,487,000, $1,270,000 and $175,000,
respectively) pursuant to an agreement, as amended (the "Supply Agreement"),
with a single German supplier, Bebig Isotopentechnik und Umweltdiagnostik GmbH.
At December 31, 2000, the Company had commitments to purchase approximately
$1,500,000 of various inventory components for the Beta-Cath(TM) System.
On October 14, 1999, the Company signed a development and manufacturing supply
agreement with AEA Technologies QSA GmbH for a second source of radioisotope
supply and for the development of a smaller diameter source. This agreement
provides for the construction of a production line over the period October 1999
to August 2001. The cost of this production line is estimated at $4,000,000 and
will be paid by the Company as construction progresses. At December 31, 2000,
the Company had a commitment remaining under this contract of approximately
$1,600,000.
Significant proportions of key components and processes relating to the
Company's products are purchased from single sources due to technology,
availability, price, quality, and other considerations. Key components and
processes currently obtained from single sources include isotopes, protective
tubing for catheters, proprietary connectors, and certain plastics used in the
design and manufacture of the transfer device. In the event a supply of a key
single-sourced material or component was delayed or curtailed, the Company's
ability to produce the related product in a timely manner could be adversely
affected. The Company attempts to mitigate these risks by working closely with
key suppliers regarding the Company's product needs and the maintenance of
strategic inventory levels.
4. INCOME TAXES
Deferred income taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the corresponding amounts used for income tax purposes. Significant
components of the Company's deferred income tax assets for federal and state
income taxes are as follows:
December 31, 2000 December 31, 1999
--------------------------------------------------
Deferred income tax assets:
Net operating loss carryforwards $ 48,342,183 $ 33,106,168
R&D tax credit carryforwards 1,881,913 1,380,352
Provision for doubtful accounts 118,298 --
Deferred revenue 220,710 --
Other 237,991 38,764
--------------------------------------------------
50,801,095 34,525,284
Valuation allowance for deferred income tax
assets (50,801,095) (34,525,284)
--------------------------------------------------
40
--------------------------------------------------
Net deferred income tax assets $ -- $ --
==================================================
At December 31, 2000 and 1999, a valuation allowance has been recognized to
reduce the net deferred tax assets to zero due to uncertainties with respect to
the Company's ability to generate taxable income in the future sufficient to
realize the benefit of deferred income tax assets. No income taxes were paid
during 2000, 1999, or 1998. The Company has approximately $127,216,000 of net
operating losses for federal income tax purposes available to offset future
taxable income. Such losses expire in 2007 through 2021 and may be subject to
annual limitations on usage due to changes in ownership. Net operating loss
carryforwards aggregating approximately $12,606,000 representing cumulative
exercises of non-qualified stock options will result in a credit to contributed
capital when recognized. The activity in the valuation allowance includes the
tax effect of these non-qualified stock options. Additionally, the Company has
$1,882,000 in research and development tax credits that expire in 2008 through
2021 unless utilized earlier.
A reconciliation of the provision for income taxes to the federal statutory rate
for the years ended December 31, 2000, 1999, and 1998 is as follows:
December 31, 2000 December 31, 1999 December 31, 1998
---------------------------------------------------------------------
Tax benefit at statutory rate $ (11,244,981) $ (10,512,872) $ (8,385,044)
State tax, net of federal benefit (1,322,939) (1,236,809) (986,475)
R&D tax credit (501,561) (361,897) (400,014)
Other 61,027 37,777 38,607
Valuation allowance 13,008,454 12,073,801 9,732,926
---------------------------------------------------------------------
$ -- $ -- $ --
=====================================================================
5. INVESTMENTS
At December 31, 2000 and 1999, short-term investments consist of debt securities
classified as available-for-sale and have maturities greater than 90 days from
the date of acquisition. All available-for-sale securities mature within one
year. The Company has invested primarily in commercial paper and U.S. corporate
notes, all of which have a minimum investment rating of A, in addition to
government agency notes and certificates of deposit. The Company had
insignificant realized gains or losses from the sale of investments for the
years ended December 31, 2000, 1999 and 1998. At December 31, 2000 and 1999,
cost of the short-term investments approximated fair value.
6. CAPITAL LEASE OBLIGATIONS
The Company leases computers and equipment under capital leases with initial or
remaining terms in excess of one year or more. During the year ended December
31, 2000, lease payments under capital leases were $71,104. Amortization of
assets recorded under capital leases is included in depreciation expense.
Future minimum lease payments under capital leases are as follows:
2001......................... $ 260,340
2002......................... 260,340
2003......................... 158,400
----------
$ 679,080
Less amounts representing interest 69,749
----------
$ 609,331
==========
7. SHAREHOLDERS' EQUITY
SHAREHOLDER RIGHTS PLAN
On October 25, 1996, the Company's Board of Directors declared a dividend of one
Right for each share of Common Stock held of record at the close of business on
November 25, 1996. The Rights are generally not exercisable until 10 days after
an announcement by the Company that a person has acquired at least 15% of the
Company's Common Stock. Each Right, should it become exercisable,
41
will entitle the owner to buy 1 1/100th of a share of new Series A participating
preferred stock at an exercise price of $85. The Rights, which do not have any
voting rights, may be redeemed by the Company at a price of $.01 per Right at
any time prior to a person's or group's acquisition of 15% or more of the
Company's Common Stock.
In the event the Rights become exercisable as a result of the acquisition of at
least 15% of the Company's Common Stock, each Right will entitle the owner,
other than the acquiring person, to buy at the Rights' then current exercise
price a number of shares of Common Stock with a market value equal to twice the
exercise price. In addition, unless the acquiring person owns more than 50% of
the outstanding shares of Common Stock, the Board of Directors may elect to
exchange all outstanding Rights (other than those owned by such acquiring person
or affiliates thereof) at an exchange ratio of one share of Common Stock per
Right. The Rights expire on November 25, 2006 unless they are earlier exercised,
redeemed, or exchanged. As a result of the adoption of the Shareholders' Rights
Plan, 1,000,000 shares of authorized preferred stock have been reserved and
designated as Series A Participating Preferred Stock.
STOCK OPTION PLANS AND STOCK GRANT
The Company's Board of Directors adopted on May 26, 1992, the Novoste
Corporation Stock Option Plan (the "Plan") under which options designated as
either incentive or non-qualified stock options may be issued to employees,
officers, directors, consultants and independent contractors of the Company or
any parent, subsidiary or affiliate of the Company. Options granted under the
Plan are at prices not less than the fair market value on the date of grant and
may be exercised for a period of ten years from the date of grant. Options
granted under the Plan have vesting periods ranging from immediately to four
years. The Plan includes a provision for options to accelerate and become
immediately and fully exercisable upon a 50% or more change in control as
defined in the Amended and Restated Stock Option Plan. The Company has reserved
2,461,179 shares of Common Stock for future issuances under the Plan. As of
December 31, 2000, there are 164,238 shares available for grant.
On August 20, 1996 the Stock Option and Compensation Committee of the Board of
Directors of the Company adopted a Non-Employee Director Stock Option Plan (the
"Director Plan"). The Company has reserved 180,500 shares of Common Stock for
future issuances under the Plan. As of December 31, 2000 there are 25,000 shares
available for grant.
Activity under the above-described two plans is summarized as follows:
WEIGHTED-
NUMBER OF PRICE PER AVERAGE
SHARES SHARE PRICE
----------------------------------------------------
Outstanding at December 31, 1997.. 1,648,363 $ .250- $24.000 $ 3.60
Options granted.................. 1,055,250 11.750 - 29.625 21.21
Options exercised................ (339,775) .250 - 16.000 3.11
Options forfeited................ (54,600) 3.200 - 24.000 10.38
-----------------
Outstanding at December 31, 1998.. 2,309,238 .250 - 29.625 11.60
Options granted.................. 715,800 11.000 - 28.375 19.42
Options exercised................ (901,815) .250 - 17.250 0.98
Options forfeited................ (53,516) 3.200 - 28.250 16.48
-----------------
Outstanding at December 31, 1999.. 2,069,707 1.000 - 29.625 18.30
Options granted.................. 978,444 20.750 - 49.250 28.83
Options exercised................ (426,544) 1.000 - 29.630 16.75
Options forfeited................ (169,166) 9.750 - 28.250 19.50
-----------------
Outstanding at December 31, 2000.. 2,452,441 $ 1.000- $49.250 22.69
=================
Exercisable at December 31, 2000.. 682,836 $ 1.000- $28.250 18.05
=================
The following table summarizes information concerning currently outstanding and
exercisable options:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------------------------------- -------------------------------
WEIGHTED
AVERAGE WEIGHTED WEIGHTED
RANGE OF REMAINING AVERAGE AVERAGE
EXERCISE NUMBER OF CONTRACTUAL EXERCISE NUMBER EXERCISE
PRICES SHARES LIFE (YEARS) PRICE EXERCISABLE PRICE
------------------- -------------- ----------------- -------------- ----------------- ------------
$ 1.00 - 13.38 520,109 7.00 $10.40 247,614 $ 9.06
13.63 - 21.94 310,388 6.69 18.74 107,638 19.53
22.50 - 22.50 495,274 9.78 22.50 2,500 22.50
42
22.88 - 24.69 511,500 7.45 23.99 277,125 24.00
24.75 - 49.25 615,170 8.62 34.08 47,959 26.67
-------------- -----------------
2,452,441 8.02 22.69 682,836 18.04
============== =================
During the period October 1998 to February 1999, options to purchase 200,000
shares were granted at prices per share ranging from $11.75 to $28.00 per share.
These grants were subject to shareholder approval in May 1999. When approval was
obtained, the market price per share exceeded the exercise price, and the
Company incurred compensation of $1,792,500, which will be expensed over the
four-year vesting period of these options ($431,000 and $532,000 in 2000 and
1999, respectively). Approximately 37,500 of these options awarded to a former
officer of the Company were forfeited during 2000.
On May 20, 1996 the Company amended an option to purchase 100,000 shares of
Common Stock at $3.20 per share of which options for 75,000 shares had not yet
become exercisable. As amended, options to purchase such 75,000 shares became
exercisable at the annual rate of 25,000 shares beginning May 20, 1997, subject
to acceleration upon the achievement of three specified milestones at the rate
of 25,000 shares per milestone. The Company recorded total non-cash compensation
expense of $810,000 ratably over the three-year period ending May 19, 1999.
Approximately $101,250 and $270,000 were expensed in 1999 and 1998,
respectively, relating to these options.
Pro forma information regarding net loss and net loss per share is required by
SFAS 123, and has been determined as if the Company had accounted for its
employee and director stock options under the fair value method of SFAS 123. The
fair value for options was estimated at the date of grant using the Black-
Scholes option-pricing model. The following weighted-average assumptions were
used for 2000, 1999 and 1998: risk-free interest rates of 5.66%, 5.20%, and
5.35%, respectively; no dividend yields; volatility factor of the expected
market price of the Company's common stock of 1.29, 0.577, and 0.736 in 2000,
1999, and 1998, respectively; and a weighted-average expected life of the option
of five years for 2000 and six years for 1999 and 1998.
Option valuation models used under SFAS 123 were developed for use in estimating
the fair value of traded options that have no vesting restrictions and are fully
transferable. In addition, option valuation models require input of highly
subjective assumptions including the expected stock price volatility. Because
the Company's stock options have characteristics significantly different from
those of traded options, and because changes in the subjective input assumptions
can materially affect the fair value estimate, in management's opinion, the
existing models do not necessarily provide a reliable single measure of the fair
value of its employee stock options.
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting period. The Company's pro
forma information follows:
Year ended December 31,
------------------------------------------------------
2000 1999 1998
----------------- ------------------ -----------------
Pro forma net loss $ (41,014,516) $ (37,131,898) $ (27,761,134)
Pro forma net loss per share (2.64) (2.76) (2.63)
Weighted-average fair value of options granted 15.98 11.30 14.61
Weighted-average fair value of non-vested
restricted stock 18.86 17.30 17.88
During 2000, 1999, and 1998, the Company has granted a total of 52,450 shares of
restricted Common Stock from the Plan to certain officers of the Company. Of
these restricted shares, 7,500 were cancelled during 2000. As of December 31,
2000, 14,333 of these restricted shares have vested. The remaining 30,716 shares
will vest over the three or four year vesting period from the date of grant
provided that the officer is still employed by the Company, and the officer has
voting rights once the shares vest. Based on the quoted market value per share
at the grant dates, the Company incurred compensation of $279,000, $231,000 and
$53,000 in 2000, 1999, and 1998, respectively. The value of the remaining shares
awarded totaled $479,000 at
43
December 31, 2000 and has been recorded as unearned compensation in the
statement of shareholders' equity. Such unearned compensation is being amortized
to compensation expense over the vesting periods of the awards.
8. EMPLOYEE BENEFIT PLANS
The Company has adopted a Defined Contribution 401(k) Plan in which all
employees who are at least 21 years of age are eligible to participate.
Contributions of up to 15% of compensation to the 401(k) Plan may be made by
employees through salary withholdings. Company matching contributions are
discretionary. In 2000, 1999, and 1998 the Company matched 33 1/3% of the first
6% of employee contributions, aggregating $124,000, $90,000 and $72,000,
respectively.
Effective July 1, 2000, the Company adopted an Employee Stock Purchase Plan
("Plan"), which makes available up to 100,000 shares of Common Stock of the
Company to be sold to eligible employees under the Plan. The purchase price of
each share of Common Stock sold pursuant to this Plan shall be the lesser of 85%
of the Fair Market Value of such share on the first day of the purchase period
or 85% of the Fair Market Value of such share on the last day of the purchase
period. As of December 31, 2000, 7,009 shares have been purchased under the
Plan.
9. SEGMENT INFORMATION
SFAS No. 131, Disclosures about Segments of an Enterprise and Related
Information ("SFAS 131") requires the reporting of segment information based on
the information provided to the company's chief operating decision maker for
purposes of making decisions about allocating resources and accessing
performance. The Company's business activities are represented by a single
industry segment, the manufacture and distribution of medical devices. For
management purposes, the Company is segmented into three geographic areas: North
America, Europe and Rest of World (Asia and South America).
The Company's net sales by geographic area are as follows:
Year Ended December 31, 2000
----------------------------------------------------------------------------
United Rest of
States Europe World Consolidated
----------------------------------------------------------------------------
2000 $1,816,250 $4,224,776 $488,555 $6,529,581
1999 18,000 1,510,000 295,000 1,823,000
1998 10,000 9,000 - 19,000
The Company's distributor for the markets of Australia, New Zealand and China
accounted for 20% of net sales in 2000 and 14% in 1999. At December 31, 2000 and
1999, the Company's net assets outside of the United States, consisting
principally of cash and cash equivalents, accounts receivable, inventory and
office equipment, were approximately $6,101,000 and $2,216,000, respectively.
44
10. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
The results of operations for the quarter ended September 30, 2000 are presented
below as previously reported and as restated to reflect the revenue recognition
policies applied in the annual financial statements for the year ended December
31, 2000.
The Company has evaluated the impact of Staff Accounting Bulletin (SAB) 101,
Revenue Recognition in Financial Statements, on its revenue recognition policies
and has concluded, based on its current understanding of the SEC's ongoing
interpretation of SAB 101, that the adoption of SAB 101 in 2000 did not require
the Company to change its revenue recognition policies in its Annual Financial
Statements. The Company had previously disclosed and reported in its Form 10-Q
for the quarter ended September 30, 2000, that the adoption of SAB 101 would
require a change in its revenue recognition policies.
First Quarter Ended Second Quarter Ended Third Quarter Ended Fourth Quarter Ended
------------------- -------------------- ---------------------------- --------------------
Fiscal 2000 March 31 June 30 September 30 September 30 December 31
-------- ------- ------------ ------------ -----------
As Previously
Reported As Restated
------------- -------------
Net sales and 846,046 1,197,647 1,445,527 1,301,771 3,184,117
- -------------- ----------- ----------- ----------- ---------- -----------
revenue
-------
Cost of sales 753,380 770,013 977,146 833,390 1,900,819
- ------------- ----------- ----------- ----------- ---------- -----------
Gross margin 92,666 427,634 468,381 468,381 1,283,298
- ------------ ----------- ----------- ----------- ---------- -----------
Loss from (7,799,879) (8,178,103) (9,807,332) (9,807,332) (11,033,625)
- ---------- ----------- ----------- ----------- ---------- -----------
operations
----------
Net loss (7,198,942) (7,129,133) (8,704,782) (8,704,782) (10,040,616)
- -------- ----------- ----------- ----------- ---------- -----------
Net loss per (.50) (.45) (.54) (.54) (.63)
- -------------
share
-----
First Quarter Ended Second Quarter Ended Third Quarter Ended Fourth Quarter Ended
------------------- -------------------- ------------------- --------------------
Fiscal 1999 March 31 June 30 September 30 December 31
-------- ------- ------------ -----------
Net sales and 80,913 553,914 566,872 621,695
- -------------- ---------------- --------------- --------------- ----------------
revenue
-------
Cost of sales 175,148 499,012 539,777 428,458
- ------------- ---------------- --------------- --------------- ----------------
Gross margin (94,235) 54,902 27,095 193,237
- ------------ ---------------- --------------- --------------- ----------------
Loss from (8,374,542) (8,155,369) (8,684,277) (7,875,486)
- ---------- ---------------- --------------- --------------- ----------------
operations
----------
Net loss (8,061,945) (7,438,342) (8,066,270) (7,353,655)
- -------- ---------------- --------------- --------------- ----------------
Net loss per (.72) (.53) (.57) (.52)
- -------------
share
-----
45
SIGNATURES
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on March 30, 2001.
NOVOSTE CORPORATION
By: s/William A. Hawkins
---------------------
William A. Hawkins
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report
has been signed below by the following persons on behalf of the Registrant and
in the capacities indicated on March 27, 2001.
s/William A. Hawkins Chief Executive Officer, President and Director
- ------------------------------ (Principal Executive Officer)
William A. Hawkins
s/Edwin B. Cordell, Jr. Chief Financial Officer
- ------------------------------ (Principal Financial and Accounting Officer)
Edwin B. Cordell, Jr.
s/Thomas D. Weldon Chairman
- ------------------------------
Thomas D. Weldon
s/Donald C. Harrison Director
- ------------------------------
Donald C. Harrison, M.D.
s/J. Stephen Holmes Director
- ------------------------------
J. Stephen Holmes
s/Charles E. Larsen Director
- ------------------------------
Charles E. Larsen
s/Pieter J. Schiller Director
- ------------------------------
Pieter J. Schiller
s/Stephen I. Shapiro Director
- ------------------------------
Stephen I. Shapiro
s/Norman R. Weldon Director
- ------------------------------
Norman R. Weldon, PhD.
s/William E. Whitmer Director
- ------------------------------
William E. Whitmer
46
INDEX TO EXHIBITS
Exhibit
Numbers Description
- ------- -----------
3.1 Articles of Incorporation of Registrant, as amended.(1)
3.2 Form of Amended and Restated Articles of Incorporation of
Registrant filed on May 28, 1996.(1)
3.2(a) Copy of First Amendment to Amended and Restated Articles of
Incorporation of Novoste Corporation filed with the Department of
State of the State of Florida on November 1, 1996.(2)
3.3(a) Copy of Amended and Restated By-Laws of Registrant adopted
December 20, 1996.(3)
4.1 Form of Specimen Common Stock Certificate of Registrant.(1)
4.2 Registration Rights Agreement, dated July 28, 1995, by and among
Registrant, Norman R. Weldon, Thomas D. Weldon, Charles E. Larsen,
the Hillman Investors (as defined therein), Noro-Moseley Partners-
III, L.P. and Advanced Technology Ventures IV, L.P.(1)
4.17(a) Amended and Restated Rights Agreement, dated as of July 29, 1999,
between Novoste Corporation and American Stock Transfer & Trust
Company, which includes as Exhibit B thereto the Form of Right
Certificate.(2)
4.17(b) Amended and Restated Summary of Rights to Purchase Preferred Shares
of Novoste Corporation.(2)
4.20 Registration Rights Agreement dated as of March 28, 2000 by and
among Novoste Corporation and the investors listed on the signature
pages thereto.(13)
*10.1 Copy of Stock Option Plan of Registrant, as amended.(3)
H10.2 License Agreement, dated January 30, 1996, between Emory University
and Registrant.(1)
H10.3 Clinical Research Study Agreement, dated January 30, 1996, by Emory
University and Registrant.(1)
47
H10.4 License Agreement, dated January 31, 1996, between Spencer B. King
III, M.D. and Registrant.(1)
H10.5 Restenosis Therapy Project Development and Supply Agreement, dated
November 28, 1994, with Registrant, relating to the supply of
radioactive beta isotopes.(1)
H10.6 Option to Purchase Assets Agreement dated August 22, 1995, with
Registrant relating to the purchase of assets of Registrant's
supplier of radioactive beta isotopes.(1)
H10.10 Frame Agreement with Bebig Isotopentechnik und Umweltdiagnostik
GmbH regarding purchases and investment grant.(3)
*10.12 Copy of Non-Employee Director Stock Option Plan.(3)
H10.13 Memorandum of Understanding between Registrant and Bebig
Isotopentechnik und Umweltdiagnostik GmbH regarding purchases and
investment grant dated April 23, 1997.(4)
10.14 Employment Agreement with William A. Hawkins III.(5)
10.16 Restricted Stock Award Agreement with William A. Hawkins III.(5)
10.17 Non-Incentive Stock Option Agreement with William A. Hawkins
III.(5)
H10.18 Amendment to Framework Agreement and Security Agreement with Bebig
GmbH.(5)
10.19 Lease, dated October 23, 1998, between Weeks Realty, L.P. and
Registrant.(6)
H10.20 Manufacturing and Supply Agreement dated April 21, 1998 between
Registrant and SeaMED Corporation.(7)
#10.20a Manufacturing and Supply Agreement dated September 1, 1999 between
Registrant and SeaMED, a Plexus Company.(11)
*10.22 Restricted Stock Award dated July 1, 1999 between Novoste
Corporation and William A. Hawkins.(9)
H10.25 Development and Manufacturing Agreement between AEA Technology -QSA
GmbH and Novoste Corporation.(10)
*10.26 Consulting Agreement, dated July 26, 1999 with Mr. Charles E.
Larsen.(11)
48
H10.27 Amendment to the Framework Agreement and Security Agreement (NOV
34) between Registrant and Bebig Isotopentechnik und
Umweltdiagnostik GmbH.(12)
10.28 Securities Purchase Agreement dated as of March 28, 2000 by and
among Novoste Corporation and the investors listed on the signature
pages thereto. (14)
23.1 Consent of Ernst & Young LLP, Independent Auditors
27 Financial Disclosure Schedule
___________________
H Portions have been omitted and filed separately with the Securities and
Exchange Commission pursuant to an order granting confidential treatment.
(1) Filed as same numbered Exhibit to the Registrant's Registration Statement
on Form S-1 (File No. 333-4988).
(2) Filed as same numbered Exhibit to the Registrant's Report on Form 8-A/A
filed on August 3, 1999.
(3) Filed as Appendix 1 and 2 to the Registrant's Proxy Statement for its 1999
Annual Meeting of Stockholders filed on April 12, 1999.
(4) Filed as same numbered Exhibit to the Registrant's Registration Statement
on Form S-3 (File No. 333-38573).
(5) Filed as same numbered Exhibit to the Registrant's Report on Form 10-Q
filed on August 11, 1998.
(6) Filed as same numbered Exhibit to the Registrant's Report on Form 10-Q
filed on November 9, 1998.
(7) Filed as same numbered Exhibit to the Registrant's Report on Form 8-K
filed on January 27,1999.
(8) Filed as same numbered Exhibit to the Registrant's Registration Statement
on Form S-3 (File No. 333-72073).
(9) Filed as same numbered Exhibit to the Registrant's Report on Form 10-Q
filed on August 11, 1999.
(10) Filed as same numbered Exhibit to the Registrant's Report on Form 10-Q
filed on November 5, 1999.
(11) Filed as same numbered Exhibit to the Registrant's Report on Form 10-K
filed on February 18, 2000
(12) Filed as same numbered Exhibit to the Registrant's Report on Form 10-Q
filed May 15, 2000
(13) Filed as same numbered Exhibit to the Registrant's Report on Form 8-K filed
April 6, 2000.
(14) Files as Exhibit 10.27 to the Registrant's Report on Form 8-K filed
April 6, 2000.
* Constitutes a compensatory plan, contract or arrangement.
49